Antibody against blood cancer
Patent Information
- Application Number
- MYPI2025003037
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-25
- Filing Date
- 2023-11-22
- Publication Date
- 2024-05-25
AI Technical Summary
Current CAR-T cell therapies for acute myeloid leukemia (AML) face challenges due to off-target effects on normal blood cells, leading to hematotoxicity, and no specific AML cell surface antigens have been effectively identified for targeted therapy.
Development of antibodies recognizing HLA-DR, specifically the KG2032 antibody, which targets AML cells and is used to create chimeric antigen receptors (CARs) for CAR-T cells and NK cells, allowing for allele-specific binding to HLA-DR on leukemia cells while sparing normal cells.
The approach enables specific targeting of AML cells, reducing harm to normal hematopoietic cells and achieving significant antitumor effects in preclinical models, with potential for improved treatment outcomes in AML patients.
Smart Images

Figure PI2025003037_DRAWING_001 
Figure PI2025003037_DRAWING_002 
Figure PI2025003037_DRAWING_003
Abstract
Description
Antibodies for blood cancers
[0001] The present invention relates to antibodies against blood cancers. More specifically, the present invention relates to antibodies or functional fragments thereof that recognize HLA-DR. The present invention also relates to chimeric antigen receptors carrying the antibodies or functional fragments thereof, or immune cells expressing the chimeric antigen receptors. Furthermore, the present invention relates to multispecific antibodies comprising the antibodies or functional fragments thereof and an antigen recognition site on immune cells. The present invention also relates to pharmaceutical compositions comprising these antibodies, etc.
[0002] Acute myeloid leukemia (AML) is one of the most common blood cancers. When chemotherapy is ineffective, allogeneic hematopoietic stem cell transplantation is indicated, which can cure many patients, but many remain incurable. One promising approach to curing such patients is immunotherapy using chimeric antigen receptor T (CAR-T) cells.
[0003] CD19 CAR-T cells have demonstrated remarkable efficacy against relapsed / refractory B-cell leukemia and malignant lymphoma (Non-Patent Documents 1 and 2). However, no CAR-T cells effective against AML exist yet. CAR-T cells targeting CD33, CD123, etc. have been developed for AML, but these have presented problems such as strong hematotoxicity due to their expression in a subset of normal blood cells (Non-Patent Documents 3 and 4).
[0004] Therefore, many attempts have been made around the world to search for AML-specific cell surface antigens that are useful for CAR-T therapy, but despite vigorous efforts using comprehensive methods such as transcriptome analysis and proteome analysis, no good targets have been found (Non-Patent Document 5).
[0005] Schuster SJ,Bishop MR,Tam CS,Waller EK,Borchmann P,McGuirk JP,et al.Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.N Engl J Med.2019;380(1):45-56.Park JH, Riviere I,Gonen M,Wang X,Senechal B,Curran KJ,et al.Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.N Engl J Med.2018;378(5):449-59.Wang, Q.S., Y. Wang, H.Y. Lv, Q.W. Han, H. Fan, B. Guo, L.L. Wang, and W.D. Han.2015.Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23:184-191.Loff, S., J. Dietrich, J.E. Meyer, J. Riewaldt, J. Spehr, M. von Bonin, C. Grunder, M. Swayampakula, K. Franke, A. Feldmann, M. Bachmann, G. Ehninger, A. Ehninger, and M. Cartellieri.2020. Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia. Mol Ther Oncolytics 17:408-420.Perna F, Berman SH, Soni RK,Mansilla-Soto J,Eyquem J,Hamieh M,et al.Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.Cancer Cell.2017;32(4):506-19 e5.Hasegawa K,Ikeda S,Yaga M,Watanabe K,Urakawa R,Iehara A,et al.Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.Sci Transl Med.2022;14(632):eaax7706. Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, et al. The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017;23(12):1436-43. ;
[0006] The present invention has been made in consideration of the problems associated with the prior art, and aims to identify cell surface antigens specific to blood cancers such as AML, and to provide antibodies or functional fragments thereof that recognize these antigens, as well as effective means for immunotherapy of blood cancers using these antibodies, etc.
[0007] The present inventors have previously found that even if a protein itself is not cancer-specific, cancer-specific epitopes formed by post-translational changes can be targets for immunotherapy (Non-Patent Documents 6 and 7).
[0008] Therefore, in order to achieve the above-mentioned object, the present inventors aimed to isolate AML-specific antibodies and develop CAR-T cells based on them by the approach of producing a large number of antibodies that bind to AML cells, identifying AML-specific antibodies from among them, and identifying the antigens that these antibodies recognize.
[0009] Specifically, we first established approximately 14,000 hybridomas secreting monoclonal antibodies (mAbs) that bind to bone marrow (BM) cells from AML patients or various AML cell lines. From these mAbs, we then selected 1,078 mAbs that did not bind to cells other than B cells in peripheral blood mononuclear cells (PBMCs) from healthy donors. Furthermore, we stained BM cells from AML patients with these candidate mAbs, and finally identified 32 mAb clones that specifically bind to AML.
[0010] Then, for one of the clones, KG2032, attempts were made to identify the antigen recognized by the antibody using the loss of binding to lymphoma cells (Daudi cells) that had been comprehensively knocked out using the CRISPR-Cas9 system as an indicator. As a result, it was revealed that the antigen recognized by KG2032 is HLA-DR. Furthermore, it was revealed that the antigen recognized by 8 clones other than KG2032 out of the 32 clones was also HLA-DR.
[0011] Furthermore, because HLA-DR is a highly polymorphic molecule, we investigated which alleles of HLA-DR KG2032 can recognize. As a result, we found that KG2032 binds to chronic myeloid leukemia cell lines (K562 cells) expressing HLA-DRB1*0405, 0410, 0701, 0803, 0901, 1201, or 1454, whereas KG2032 does not bind to K562 cells expressing HLA-DRB1*0101, 0301, 0403, 0404, 0802, 1101, 1301, 1302, 1403, 1405, 1406, 1501, or 1502.
[0012] It was also revealed that KG2032 does not bind to some monocytes and T cells expressing HLA-DR.
[0013] Furthermore, the amino acid sequence of the variable region of KG2032 was identified, and a chimeric antigen receptor was designed in which this region was fused with CD28 and CD3ζ, or CD8α, 4-1BB, and CD3ζ. T cells expressing this chimeric antigen receptor (CAR-T cells) were then prepared and cocultured with a human acute myeloid leukemia-derived cell line (KG1a cells). The results demonstrated that the CAR-T cells produced cytokines such as IFN-γ and IL-2 and exhibited cytotoxic activity. Furthermore, when the CAR-T cells were administered to mice transfected with KG1a cells, a significant antitumor effect was observed.
[0014] Furthermore, a vector was constructed for co-expressing a chimeric antigen receptor in which CD28 and CD3ζ were fused to the variable region of KG2032, and IL-15. NK cells expressing this chimeric antigen receptor (CAR-NK cells) were then prepared and co-cultured with a human acute myeloid leukemia-derived cell line (KG1a cells). The results demonstrated that the CAR-NK cells exhibited cytotoxic activity. Furthermore, it was found that administration of the CAR-NK cells to mice transfected with KG1a cells resulted in a significant antitumor effect.
[0015] From these results, the present inventors discovered that the use of an antibody that recognizes HLA-DR, such as KG2032, in the treatment of blood cancers may enable the following application modes (1) and (2), and thus completed the present invention.
[0016] (1) In an AML patient who has relapsed after HLA-DR-mismatched allogeneic transplantation, when the recipient (leukemia patient) has a positive HLA-DR antibody and the donor has a negative HLA-DR antibody, it is believed that the anti-HLA-DR antibody-derived CAR-T cells produced from T cells derived from the transplanted patient himself or the donor will specifically attack the leukemia in the recipient.
[0017] (2) By using an anti-HLA-DR antibody that binds only to some normal blood cells, such as B cells, and only to some hematopoietic stem cells, which are the source of all blood cells, even if normal autologous CAR-T cells are used in the treatment of an AML patient with an HLA-DR type that is positive for the anti-HLA-DR antibody, it is thought that leukemia cells will be eliminated and normal hematopoiesis will be maintained by the anti-HLA-DR antibody-negative cells, and therefore the treatment is considered to be viable.
[0018] That is, the present invention provides the following aspects.
[0019] [1] A composition for treating blood cancer, comprising an antibody that recognizes HLA-DR or a functional fragment thereof.
[0020] [2] A composition to be administered to a patient with blood cancer who has received a hematopoietic stem cell transplant, the composition comprising an antibody or a functional fragment thereof that recognizes HLA-DR, wherein the donor of the hematopoietic stem cells and the patient have different HLA-DR allele types, and the antibody or the functional fragment thereof binds to the HLA-DR of the patient but does not bind to the HLA-DR of the donor.
[0021] [3] The composition according to [1] or [2], wherein the antibody or functional fragment thereof recognizes HLA-DRB.
[0022] [4] The composition according to [1] or [2], wherein the antibody or functional fragment thereof recognizes HLA-DRB1.
[0023] [5] The antibody or functional fragment thereof is selected from the group consisting of HLA-DRB1*0405, HLA-DRB1*0410, HLA-DRB1*0701, HLA-DRB1*0803, HLA-DRB1*0901, HLA-DRB1*1201, HLA-DRB1*1454, HLA-DRB1*0101, HLA-DRB1*0301, HLA-DRB1*0403, HLA-DRB1*0404, HLA-DRB1*0501, HLA-DRB1*0601 ...601, HLA-DRB1*0601, HLA-DRB1*0602, HLA-DRB1*0603, HLA-DRB1*0604, HLA-DRB1*0605, HLA- The composition according to [1] or [2], which binds to at least one HLA-DRB1 allele selected from the group consisting of HLA-DRB1*0802, HLA-DRB1*1101, HLA-DRB1*1301, HLA-DRB1*1302, HLA-DRB1*1403, HLA-DRB1*1405, HLA-DRB1*1406, HLA-DRB1*1501, and HLA-DRB1*1502.
[0024] [6] The composition according to [1] or [2], wherein the antibody or functional fragment thereof binds to an HLA-DRB1 allele in which position 86 is an amino acid other than aspartic acid, but does not bind to an HLA-DRB1 allele in which position 86 is aspartic acid.
[0025] [7] The antibody or functional fragment thereof binds to at least one HLA-DRB1 allele selected from the group consisting of HLA-DRB1*0405, HLA-DRB1*0410, HLA-DRB1*0701, HLA-DRB1*0803, HLA-DRB1*0901, HLA-DRB1*1201, and HLA-DRB1*1454, and also binds to HLA-DRB1*0101, HLA-DRB1*0301, HLA-DRB1*0403, HLA-DRB1*0901, HLA-DRB1*1201, and HLA-DRB1*1454. The composition according to [1] or [2], which does not bind to at least one HLA-DRB1 allele selected from the group consisting of HLA-DRB1*0404, HLA-DRB1*0802, HLA-DRB1*1101, HLA-DRB1*1301, HLA-DRB1*1302, HLA-DRB1*1403, HLA-DRB1*1405, HLA-DRB1*1406, HLA-DRB1*1501, and HLA-DRB1*1502.
[0026] [8] The composition according to any one of [1] to [7], comprising an immune cell expressing a chimeric antigen receptor carrying the antibody or a functional fragment thereof.
[0027] [9] The composition according to [8], wherein the immune cells are prepared from cells derived from a donor of the hematopoietic stem cells.
[0028]
[10] The composition according to [9], wherein the cells derived from the hematopoietic stem cell donor are pluripotent stem cells.
[0029]
[11] The composition according to any one of [1] to [7], comprising a multispecific antibody that retains the antibody or a functional fragment thereof and an antigen recognition site on an immune cell.
[0030]
[12] The composition according to any one of [1] to [7], wherein the antibody or functional fragment thereof does not bind to some normal blood cells.
[0031]
[13] The composition according to any one of [1] to [7], wherein the antibody or functional fragment thereof does not bind to monocytes.
[0032]
[14] The composition according to
[13] , comprising immune cells expressing a chimeric antigen receptor carrying the antibody or a functional fragment thereof.
[0033]
[15] The composition according to
[13] , comprising a multispecific antibody comprising the antibody or a functional fragment thereof and an antigen recognition site on an immune cell.
[0034]
[16] An antibody or functional fragment thereof that recognizes HLA-DR, which binds to a region containing the amino acid sequence of positions 74 to 89 of HLA-DRB1 in which the amino acid at position 86 is an amino acid other than aspartic acid, but does not bind to a region containing the amino acid sequence of positions 74 to 89 of HLA-DRB1 in which the amino acid at position 86 is aspartic acid.
[0035]
[17] An antibody or functional fragment thereof that recognizes HLA-DR, having any of the following characteristics (a) to (i): (a) having a heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 1 to 3, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 5 to 7; (b) having a heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 34 to 36, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 38 to 40; (c) having a heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 42 to 44, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 46 to 48. (d) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 50 to 52, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 54 to 56. (e) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 58 to 60, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62 to 64. (f) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 66 to 68, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62 to 64. (g) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 70 to 72, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62 to 64. (h) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 74 to 76, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62 to 64. (i) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 66 to 68, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62, 78, and 64.
[0036]
[18] A chimeric antigen receptor carrying the antibody or functional fragment thereof according to
[16] or
[17] .
[0037]
[19] An immune cell expressing a chimeric antigen receptor carrying the antibody or functional fragment thereof according to
[16] or
[17] .
[0038]
[20] The immune cell according to
[19] , to which the antibody or functional fragment thereof according to
[16] or
[17] does not bind.
[0039]
[21] The immune cell according to
[19] or
[20] , which is at least one cell selected from the group consisting of T cells, NK cells, and NKT cells.
[0040]
[22] A pharmaceutical composition comprising the antibody or functional fragment thereof according to
[16] or
[17] , or the immune cell according to any one of
[19] to
[21] .
[0041]
[23] The pharmaceutical composition according to
[22] , for treating blood cancer.
[0042]
[24] The pharmaceutical composition according to
[23] , wherein the immune cells are prepared from cells derived from a human other than the blood cancer patient to be treated.
[0043]
[25] The pharmaceutical composition according to
[23] , wherein the immune cells are prepared from cells collected from a patient with blood cancer to be treated.
[0044]
[26] A method for producing the pharmaceutical composition according to
[23] , comprising the step of modifying an immune cell to which the antibody or functional fragment thereof according to
[16] or
[17] does not bind, so that the immune cell expresses the chimeric antigen receptor according to
[18] .
[0045]
[27] The method according to
[26] , wherein the immune cells are derived from a human other than the blood cancer patient to be treated.
[0046]
[28] The method according to
[26] , wherein the immune cells are cells collected from a blood cancer patient to be treated.
[0047]
[29] The method according to any one of
[26] to
[28] , wherein the immune cell is at least one cell selected from the group consisting of a T cell, a NK cell, and a NKT cell.
[0048] According to the present invention, by targeting HLA-DR, which is a cell surface antigen specific to blood cancer, it becomes possible to treat the above-mentioned diseases by using an antibody or a functional fragment thereof that recognizes the antigen, or a chimeric antigen receptor (CAR) that retains the same.
[0049] In particular, since such antibodies can exhibit allele specificity for HLA-DR, in the case of a blood cancer patient who has relapsed after HLA-DR-mismatched allogeneic transplantation, if the recipient (blood cancer patient) has positive HLA-DR to which the antibody of the present invention binds and the donor has negative HLA-DR to which the antibody of the present invention does not bind, CAR-T cells or the like derived from the antibody of the present invention, which are produced from donor-derived cells including pluripotent stem cells, can specifically attack the blood cancer in the recipient.
[0050] Furthermore, even if the antibody of the present invention is used in treatment of blood cancer patients having positive HLA-DR to which the antibody of the present invention binds, using conventional autologous CAR-T cells or the like, blood cancer cells are eliminated and normal hematopoiesis is maintained by negative cells to which the antibody of the present invention does not bind, making it possible to treat the patient.
[0051]
[0033] Figure 2B shows the results of flow cytometry analysis of the binding of KG2032 to peripheral blood from healthy individuals. In the figure, T represents T cells, B represents B cells, Mo represents monocytes, and Neu represents neutrophils.
[0034] Figure 2C shows the results of flow cytometry analysis of the binding of KG2032 to AML specimens. Case numbers (unique patient numbers: UPN) 1 to 14 indicate leukemia cells derived from each AML patient.
[0035] Figure 2D shows an overview of the process for identifying the antigen recognized by KG2032 using a CRISPR guide RNA (gRNA) library.
[0036] Figure 2E shows the results of flow cytometry analysis of the binding of KG2032 to the Cas9-expressing Daudi cells shown in Figure 2A. More specifically, after introduction of the gRNA library shown in Figure 2A, cell fractions with reduced binding of KG2032 were sorted.
[0033] Figure 1 shows the results of analyzing the binding of KG2032 to cells before and after sorting. Figure 2 shows a plot of the frequency of gRNA introduced into cells after sorting and before sorting. Figure 3 shows the results of flow cytometry analysis of the binding of KG2032 or an existing anti-HLA-DR antibody (L243) to Daudi cells in which HLA-DR molecules have been knocked out. Figure 4 shows the results of flow cytometry analysis of the binding of KG2053, KG1982, KG19122, KG19130, KG19214, KG19833, aAML191870, or aAML191872 to Daudi cells in which HLA-DR molecules have been knocked out. Figure 5 shows the results of flow cytometry analysis of the binding of KG2032 or L243 to K562 cells in which various HLA-DRB1 molecules have been expressed. 1 shows the results of flow cytometry analysis of the binding of KG2032 or L243 to each peripheral blood fraction from a healthy subject (donor 1) with KG2032-negative HLA-DRB1 (0403 / 0802) or each peripheral blood fraction from a healthy subject (donor 2) with KG2032-positive HLA-DRB1 (0403 / 0901).
[0023] FIG. 1 shows the results of flow cytometry analysis of the binding of KG2032 to bone marrow cells from an AML patient with KG2032-positive HLA-DRB1.
[0023] Figure 1 shows the results of flow cytometry analysis of the binding of KG2032 to each fraction of bone marrow cells from healthy individuals with KG2032-positive HLA-DRB1. Figure 2 shows an outline of the use of KG2032 in AML treatment. Figure 3 shows an outline of another use of KG2032 in AML treatment. Figure 4 shows the results of a comparison of the amino acid sequences of DRB1*1454 (KG2032-positive) and DRB1*1502 (KG2032-negative). In the figure, Regions 1 to 5 each indicate regions with significant differences in the amino acid sequence. Figure 5 shows an outline of a chimeric protein formed by partially fusing HLA-DRB1*1454 (KG2032-positive) and HLA-DRB1*1502 (KG2032-negative).
[0023] Figure 1 shows the results of flow cytometry analysis of the binding of KG2032 or L243 to K562 cells expressing each of the various chimeric proteins.
[0024] Figure 1 shows the results of comparing the amino acid sequences of Region 3 between K562 cells expressing various HLA-DRB1 molecules to which KG2032 binds and those to which it does not.
[0025] Figure 1 shows the results of comparing the binding of KG2032 or L243 to K562 cells expressing a mutant in which the amino acid serine (S) at position 86 of DRB1*0405 (KG2032-positive) is substituted with aspartic acid (D).
[0026] Figure 1 shows an outline of a chimeric antigen receptor (KG2032-CAR) comprising the variable region of KG2032.
[0027] Figure 1 shows the results of analysis of the transduction rate of KG2032-CAR.
[0028] Figure 1 is a graph showing the proliferation rate of T cells expressing KG2032-CAR (KG2032-CAR-T cells). In the figure, "Control" indicates T cells that have not been transfected with a gene. This graph shows the results of analyzing cytokine production after 24 hours of co-culture of KG2032-CAR-T cells with the leukemia cell line KG1a (KG2032-positive) or THP-1 (KG2032-negative). This graph shows the results of analyzing cytotoxic activity after 4 hours of co-culture of KG2032-CAR-T cells with the leukemia cell line KG1a or THP-1. This graph shows the results of analyzing the proliferation of KG2032-CAR-T cells with and without the addition of dasatinib. Note that in Figure 8F and subsequent figures, the results are shown using "BBζ" shown in Figure 8A as KG2032-CAR-T.
[0033] Figure 1 shows the results of flow cytometry analysis of the expression of T cell exhaustion markers (PD-1, LAG-3, TIM-3) in KG2032-CAR-T cells with and without the addition of dasatinib. Figure 2 shows a graph depicting the results of analysis of IL-2 production in coculture of KG2032-CAR-T cells and KG1a cells with and without the addition of dasatinib. Figure 3 shows the results of analysis of the effect of KG2032-CAR-T cell administration in a xenograft model in which luciferase-expressing KG1a cells were transplanted into NOG mice, by detecting bioluminescence using an in vivo imaging system (IVIS). Figure 4 shows the results of analysis of the effect of KG2032-CAR-T cell administration in a xenograft model in which luciferase-expressing KG1a cells were transplanted into NOG mice. The graph shows the time course of luminescence intensity detected by IVIS.
[0023] Figure 1 is a diagram showing an outline of the manufacturing process for KG2032 CAR-T2A-IL-15 and NK cells transfected with the CAR.
[0024] Figure 2 is a graph showing the results of analyzing the proliferation of NK cells transfected with KG2032 CAR-T2A-IL-15 (KG2032 CAR-NK) or control (non-transfected (NT)) NK cells during in vitro culture.
[0025] Figure 3 is a graph showing the results of analyzing the expression of CD56, CD3, and KG2032 CAR in KG2032 CAR-NK by flow cytometry.
[0026] Figure 4 is a graph showing the results of measuring CD107a degranulation when KG2032 CAR-NK or control NK cells are co-cultured with target cells, measuring the cytotoxic activity when KG2032 CAR-NK or control NK cells are co-cultured with target cells. 511 is a graph showing the results of measurements by Cr release assay. This is a diagram showing the timing of transplantation of KG1a AML cells (KG1a-luc) and administration of KG2032 CAR-NK into immunodeficient mice. This is a graph showing the survival rate of KG1a-transplanted mice administered with KG2032 CAR-NK. This is a diagram showing the results of detecting and analyzing bioluminescence in mice injected with KG2032 CAR-NK or control NK cells (n=4 per group). This is a diagram showing the timing of transplantation of AML patient-derived bone marrow cells and administration of modified KG2032 CAR-T cells into immunodeficient mice. This is a diagram showing the results of flow cytometry analysis of bone marrow cells from mice injected with modified KG2032 CAR-T cells or control T cells. This shows an analysis of a cell population previously gated as mouse CD45-negative cells. This shows human CD45 expression in bone marrow cells and mouse CD45-negative cells 31 days after AML cell transplantation. + human CD3 - Human CD34 + FIG. 1 is a dot plot showing the percentage of AML cells.
[0052] <Anti-HLA-DR Antibody> The present invention relates to an antibody or a functional fragment thereof that recognizes HLA-DR, a class II major histocompatibility complex (MHC). In the present invention, "recognizing HLA-DR" means binding to at least one allele type in HLA-DR, and also includes binding to at least one allele type in HLA-DR without binding to at least one other allele type.
[0053] Examples of HLA-DR allele types include HLA-DR1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR5, HLA-DR6, HLA-DR7, HLA-DR8, HLA-DR9, HLA-DR10, HLA-DR11, HLA-DR12, HLA-DR13, HLA-DR14, HLA-DR15, HLA-DR52, and HLA-DR53. HLA-DR is, for example, a complex of an α chain and a β chain, and more specifically, the α chain includes HLA-DRA such as HLA-DRA1. Examples of the β chain include HLA-DRB such as HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5. Furthermore, examples of HLA-DRB1 include HLA-DRB1*0405 (SEQ ID NO: 11), HLA-DRB1*0410 (SEQ ID NO: 12), HLA-DRB1*0701 (SEQ ID NO: 13), HLA-DRB1*0803 (SEQ ID NO: 14), HLA-DRB1*0901 (SEQ ID NO: 15), HLA-DRB1*1201 (SEQ ID NO: 16), HLA-DRB1*1454 (SEQ ID NO: 17), HLA-DRB1*0101 (SEQ ID NO: 18), HLA-DRB1*0301 (SEQ ID NO: 19), and HLA-DRB1*0403 (SEQ ID NO: 20). HLA-DRB1*0404 (SEQ ID NO: 20), HLA-DRB1*0404 (SEQ ID NO: 21), HLA-DRB1*0802 (SEQ ID NO: 22), HLA-DRB1*1101 (SEQ ID NO: 23), HLA-DRB1*1301 (SEQ ID NO: 24), HLA-DRB1*1302 (SEQ ID NO: 25), HLA-DRB1*1403 (SEQ ID NO: 26), HLA-DRB1*1405 (SEQ ID NO: 27), HLA-DRB1*1406 (SEQ ID NO: 28), HLA-DRB1*1501 (SEQ ID NO: 29), and HLA-DRB1*1502 (SEQ ID NO: 30).
[0054] The antibody of the present invention includes, for example, an antibody that binds to an allele of HLA-DRB1 in which an amino acid other than aspartic acid is present at position 86. Furthermore, the antibody may not bind to an allele of HLA-DRB1 in which an amino acid other than aspartic acid is present at position 86. The "amino acid other than aspartic acid" at position 86 is preferably serine, valine, or alanine.
[0055] More specific examples include antibodies that bind to at least one (e.g., 1, 2, 3, 4, 5, 6, or 7) HLA-DRB selected from the group consisting of HLA-DRB1*0405 (SEQ ID NO: 11), HLA-DRB1*0410 (SEQ ID NO: 12), HLA-DRB1*0701 (SEQ ID NO: 13), HLA-DRB1*0803 (SEQ ID NO: 14), HLA-DRB1*0901 (SEQ ID NO: 15), HLA-DRB1*1201 (SEQ ID NO: 16), and HLA-DRB1*1454 (SEQ ID NO: 17). On the other hand, HLA-DRB1*0101 (SEQ ID NO: 18), HLA-DRB1*0301 (SEQ ID NO: 19), HLA-DRB1*0403 (SEQ ID NO: 20), HLA-DRB1*0404 (SEQ ID NO: 21), HLA-DRB1*0802 (SEQ ID NO: 22), HLA-DRB1*1101 (SEQ ID NO: 23), HLA-DRB1*1301 (SEQ ID NO: 24), HLA-DRB1*1302 (SEQ ID NO: 25), The antibody of the present invention may be an antibody that does not bind to at least one HLA-DR selected from the group consisting of HLA-DRB1*1403 (SEQ ID NO: 26), HLA-DRB1*1405 (SEQ ID NO: 27), HLA-DRB1*1406 (SEQ ID NO: 28), HLA-DRB1*1501 (SEQ ID NO: 29), and HLA-DRB1*1502 (SEQ ID NO: 30) (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13). Furthermore, as shown in the Examples below, the antibody of the present invention can recognize a region comprising the amino acid sequence of positions 74 to 89 of HLA-DRB1. Alternatively, the antibody of the present invention may not bind to a portion of monocytes or T cells.
[0056] Those skilled in the art can analyze whether an antibody has such binding ability by immunological techniques. For example, as shown in the Examples below, in antigen analysis by flow cytometry, if the peak derived from the test antibody is shifted to a stronger fluorescence intensity compared to the peak derived from its isotype control antibody, it can be determined that the test antibody (substantially) binds to the antigen. On the other hand, if no such shift is observed, it can be determined that the test antibody does not (substantially) bind to the antigen.
[0057] The binding affinity of the antibody of the present invention is D (dissociation constant) is 10 -7 Preferably, it is 10 -8 It is more preferable that K is equal to or less than K. D is calculated from ka (association rate constant) and kd (dissociation rate constant) (K D = kd / ka). Ka and kd are rate constants in the binding / dissociation reaction between two molecules, and can be determined, for example, by measurement using surface plasmon resonance (SPR). SPR measurement of the binding between an antibody and an antigen is well known, and a person skilled in the art can determine the k and k of an antibody based on such well-known techniques, and further, K D can be calculated.
[0058] The term "antibody" as used herein includes all classes and subclasses of immunoglobulins. "Antibody" includes polyclonal and monoclonal antibodies. A "polyclonal antibody" is an antibody preparation containing different antibodies directed against different epitopes. A "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies. In contrast to polyclonal antibodies, monoclonal antibodies recognize a single determinant on an antigen. The antibody of the present invention is preferably a monoclonal antibody. The antibody of the present invention is an antibody that has been separated and / or recovered (i.e., isolated) from components of its natural environment.
[0059] The antibody of the present invention may have at least one cytotoxic activity selected from ADCC activity and CDC activity, or may have both ADCC activity and CDC activity.
[0060] In the present invention, "ADCC activity (antibody-dependent cellular cytotoxicity)" refers to the activity of an antibody binding to a cell surface antigen on a target cell, whereby effector cells (immune cells such as NK cells and monocytes) are further bound to the Fc region of the antibody, activating the cells and releasing factors to kill the target cells. On the other hand, "CDC activity (complement-dependent cytotoxicity)" refers to the activity of an antibody binding to a target cell, activating the complement system, resulting in lysis of the target cell.
[0061] The antibody of the present invention may also have antitumor activity. In the present invention, "antitumor activity" means at least one of the activities of suppressing cancer cell proliferation, inducing cancer cell death, and suppressing cancer cell metastasis. Antitumor activity can be evaluated, for example, by analysis using a cancer-bearing model as shown in the Examples below. Even without using such an in vivo system, tumor cells can be cultured in the presence or absence of a test antibody, and if the number of tumor cells in the former is reduced compared to the latter, the antibody can be determined to have antitumor activity.
[0062] The antibody of the present invention is not particularly limited as long as it can recognize HLA-DR, and its origin, type, shape, etc. Specific examples include antibodies derived from non-human animals (e.g., mouse antibodies, rabbit antibodies, rat antibodies, and camel antibodies), antibodies derived from humans, chimeric antibodies, and humanized antibodies.
[0063] In the present invention, examples of "antibodies derived from non-human animals" include KG2032, KG2053, KG1982, KG19130, KG19214, KG19833, aAML191870, aAML191872, and KG19122, which are shown in the Examples below. More specifically, examples include antibodies having variable regions containing the following amino acid sequences: (a) an antibody having a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 4 and a light chain variable region containing the amino acid sequence of SEQ ID NO: 8; (b) an antibody having a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 37 and a light chain variable region containing the amino acid sequence of SEQ ID NO: 41; (c) an antibody having a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 45 and a light chain variable region containing the amino acid sequence of SEQ ID NO: 49; and (d) an antibody having a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 53 and a light chain variable region containing the amino acid sequence of SEQ ID NO: 57. (e) An antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 61, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65. (f) An antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 69, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65. (g) An antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 73, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65. (h) An antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 77, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65. (i) An antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 69, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 79.
[0064] Further examples include antibodies that recognize HLA-DR and have the following complementarity-determining regions (CDRs): (a) an antibody that has heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. (b) an antibody that has heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 37 and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence of SEQ ID NO: 41. (c) an antibody that has heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 45 and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49. (d) an antibody that has heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53 and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence of SEQ ID NO: 57. (e) An antibody having heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 61, and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65. (f) An antibody having heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 69, and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65. (g) An antibody having heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 73, and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65. (h) An antibody having heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 77 and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 65. (i) An antibody having heavy chain CDR1 to 3 determined from a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 69 and light chain CDR1 to 3 determined from a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 79.
[0065] Regarding such antibodies, the method for determining CDRs based on the amino acid sequences of the variable regions is not particularly limited, and examples include known numbering schemes such as Kabat, Chothia, IMGT, and Aho. More specifically, examples of CDRs determined by Kabat include antibodies that recognize HLA-DRs having the following CDRs: (a) an antibody having the amino acid sequences set forth in SEQ ID NOs: 1 to 3 as heavy chain CDRs 1 to 3, respectively, and the amino acid sequences set forth in SEQ ID NOs: 5 to 7 as light chain CDRs 1 to 3, respectively; (b) an antibody having the amino acid sequences set forth in SEQ ID NOs: 34 to 36 as heavy chain CDRs 1 to 3, respectively, and the amino acid sequences set forth in SEQ ID NOs: 38 to 40 as light chain CDRs 1 to 3, respectively; and (c) an antibody having the amino acid sequences set forth in SEQ ID NOs: 42 to 44 as heavy chain CDRs 1 to 3, respectively, and the amino acid sequences set forth in SEQ ID NOs: 46 to 48 as light chain CDRs 1 to 3, respectively. (d) An antibody having the amino acid sequences set forth in SEQ ID NOs: 50 to 52 as heavy chain CDR1 to 3, respectively, and the amino acid sequences set forth in SEQ ID NOs: 54 to 56 as light chain CDR1 to 3, respectively. (e) An antibody having the amino acid sequences set forth in SEQ ID NOs: 58 to 60 as heavy chain CDR1 to 3, respectively, and the amino acid sequences set forth in SEQ ID NOs: 62 to 64 as light chain CDR1 to 3, respectively. (f) An antibody having the amino acid sequences set forth in SEQ ID NOs: 66 to 68 as heavy chain CDR1 to 3, respectively, and the amino acid sequences set forth in SEQ ID NOs: 62 to 64 as light chain CDR1 to 3, respectively. (g) An antibody having the amino acid sequences set forth in SEQ ID NOs: 70 to 72 as heavy chain CDR1 to 3, respectively, and the amino acid sequences set forth in SEQ ID NOs: 62 to 64 as light chain CDR1 to 3, respectively. (h) An antibody having the amino acid sequences set forth in SEQ ID NOs: 74 to 76 as heavy chain CDR1 to 3, respectively, and the amino acid sequences set forth in SEQ ID NOs: 62 to 64 as light chain CDR1 to 3, respectively. (i) An antibody having the amino acid sequences set forth in SEQ ID NOs: 66 to 68 as heavy chain CDR1 to 3, and the amino acid sequences set forth in SEQ ID NOs: 62, 78, and 64 as light chain CDR1 to 3, respectively.
[0066] Furthermore, the present invention encompasses not only antibodies that retain variable regions and / or CDRs consisting of such specific amino acid sequences, but also antibodies whose amino acid sequences have been modified without reducing desired activity (such as reactivity with an antigen). Such amino acid sequence variants can be produced, for example, by introducing mutations into DNA encoding the above-mentioned variable regions, etc., or by peptide synthesis. Such modifications include, for example, substitution, deletion, addition, and / or insertion of residues within the amino acid sequence of the antibody. The site where the amino acid sequence of the antibody is modified may be the constant region of the heavy or light chain of the antibody, or may be the variable region (framework region (FR) and CDR) as long as the activity is equivalent to that of the antibody before modification. Since modifications of amino acids other than those in the CDRs are thought to have relatively little effect on reactivity with an antigen, modifications are usually made to the FR. However, currently, techniques are known for screening antibodies with increased affinity to antigens by modifying amino acids in the CDRs (PNAS, 102: 8466-8471 (2005), Protein Engineering, Design & Selection, 21: 485-493 (2008), WO 2002 / 051870, J. Biol. Chem., 280: 24880-24887 (2005), Protein Engineering, Design & Selection, 21: 345-351 (2008), MAbs. Mar-Apr; 6(2): 437-45 (2014)). Currently, it is also possible to model antibodies with enhanced antigen affinity by utilizing an integrated computational chemistry system (e.g., Molecular Operating Environment, manufactured by CCG, Canada) (see, for example, http: / / www.rsi.co.jp / kagaku / cs / ccg / products / application / protein.html). Furthermore, as described in Protein Eng Des Sel. 2010 Aug;23(8):643-51, there are known examples in which CDR1 of the heavy chain variable region and CDR3 of the light chain variable region are not involved in antigen affinity.Similarly, Molecular Immunology 44:1075-1084 (2007) reports that in most antibodies, CDR2 of the light chain variable region is not involved in antigen affinity. Thus, antibody affinity for an antigen can exhibit equivalent activity even without requiring all of CDR1 to CDR3 of each of the heavy chain variable region and the light chain variable region. In fact, Biochem Biophys Res Commun. 2003 Jul 18;307(1):198-205, J Mol Biol. 2004 Jul 9;340(3):525-42, J Mol Biol. 2003 Aug 29;331(5):1109-20 reports an example in which affinity for an antigen was maintained by retaining at least one CDR of the original antibody.
[0067] Furthermore, with regard to the antibodies of the present invention, the number of amino acids to be altered in the variable region is preferably 10 amino acids or less, more preferably 5 amino acids or less, and even more preferably 3 amino acids or less (e.g., 2 amino acids or less, 1 amino acid or less). Furthermore, from the viewpoint of minimizing the effect on antigen binding, it is preferable that all such alterations are made in regions other than the CDRs, i.e., in the FRs. Furthermore, the number of amino acids to be altered in the CDRs is preferably 5 amino acids or less, more preferably 3 amino acids or less (e.g., 2 amino acids or less, 1 amino acid or less).
[0068] The amino acid modification is preferably a conservative substitution. In the present invention, "conservative substitution" refers to substitution with another amino acid residue that is similar (having a chemically similar side chain). Groups of amino acid residues with chemically similar amino acid side chains are well known in the art to which the present invention pertains. For example, acidic amino acids (aspartic acid and glutamic acid), basic amino acids (lysine, arginine, histidine), and neutral amino acids can be classified into amino acids with hydrocarbon chains (glycine, alanine, valine, leucine, isoleucine, proline), amino acids with hydroxyl groups (serine, threonine), sulfur-containing amino acids (cysteine, methionine), amino acids with amide groups (asparagine, glutamine), amino acids with imino groups (proline), and amino acids with aromatic groups (phenylalanine, tyrosine, tryptophan).
[0069] Furthermore, antibodies having a variable region containing an amino acid sequence after modification that has 80% or more homology or identity at the amino acid sequence level with a variable region consisting of the above-mentioned specific amino acid sequence are also included in the antibodies of the present invention, as long as they have activity equivalent to that of the antibody before modification. Such homology or identity may be at least 80%, but is preferably 85% or more, more preferably 90% or more, and even more preferably 95% or more (e.g., 96% or more, 97% or more, 98% or more, 99% or more). It is preferable that modifications in the variable region of such antibodies are made to a region other than the CDR, i.e., the FR, from the viewpoint of minimizing the impact on antigen binding. Furthermore, "identity" refers to the proportion of sites where the type of amino acid is identical between the amino acid sequences being compared, and "homology" refers to the proportion of sites where similar amino acids are identical, plus the proportion of sites where similar amino acids are identical. Sequence homology or identity can be determined using the BLASTP (amino acid level) program (Altschul et al. J. Mol. Biol., 215:403-410, 1990). This program is based on the BLAST algorithm by Karlin and Altschul (Proc. Natl. Acad. Sci. USA, 87:2264-2268, 1990, Proc. Natl. Acad. Sci. USA, 90:5873-5877, 1993). When analyzing amino acid sequences using BLASTP, the parameters are, for example, score=50 and wordlength=3. Furthermore, when analyzing amino acid sequences using the Gapped BLAST program, the method can be performed as described by Altschul et al. (Nucleic Acids Res. 25: 3389-3402, 1997). When using the BLAST and Gapped BLAST programs, the default parameters of each program are used. Specific techniques for these analysis methods are known.
[0070] Furthermore, "having equivalent activity" means, for example, that the antigen-binding ability is equivalent (e.g., 70% or more, preferably 80% or more, more preferably 90% or more) to that of a reference antibody (e.g., KG2032, KG2053, KG1982, KG19130, KG19214, KG19833, aAML 191870, aAML 191872, KG19122).
[0071] Modification of the antibodies of the present invention may also involve modification of the post-translational process of the antibody, such as changing the number or location of glycosylation sites. This can improve, for example, the ADCC activity of the antibody. Antibody glycosylation is typically N-linked or O-linked. Antibody glycosylation largely depends on the host cell used to express the antibody. Glycosylation patterns can be modified by known methods, such as introducing or deleting specific enzymes involved in sugar production (see JP 2008-113663 A, U.S. Pat. Nos. 5,047,335, 5,510,261, 5,278,299, and WO 99 / 54342). Furthermore, in the present invention, deamidation may be suppressed by substituting a deamidated amino acid or an amino acid adjacent to a deamidated amino acid with another amino acid, for purposes such as increasing antibody stability. Furthermore, antibody stability can be increased by substituting glutamic acid with another amino acid. The present invention also provides antibodies stabilized in this manner.
[0072] In the present invention, a "chimeric antibody" refers to an antibody in which the variable region of one antibody is linked to the constant region of a heterologous antibody. Chimeric antibodies can be obtained, for example, by immunizing a mouse with an antigen, excising the antibody variable region (variable region) that binds to the antigen from the mouse monoclonal antibody gene, ligating it to an antibody constant region (constant region) gene derived from human bone marrow, incorporating it into an expression vector, and introducing it into a host for production (e.g., JP-A-8-280387, U.S. Pat. No. 4,816,397, U.S. Pat. No. 4,816,567, U.S. Pat. No. 5,807,715).
[0073] The constant region of a chimeric antibody is usually derived from a human antibody. For example, Cγ1, Cγ2, Cγ3, Cγ4, Cμ, Cδ, Cα1, Cα2, and Cε can be used as the heavy chain constant region. Furthermore, Cκ and Cλ can be used as the light chain constant region. The amino acid sequences of these constant regions and the nucleotide sequences encoding them are known. Furthermore, to improve the stability of the antibody itself or the stability of antibody production, one or several amino acids in the human antibody constant region can be substituted, deleted, added, and / or inserted.
[0074] In the present invention, a "humanized antibody" refers to an antibody in which the CDR gene sequence of an antibody derived from a non-human animal has been grafted onto a human antibody gene (CDR grafting). Methods for producing such an antibody include known techniques such as overlap extension PCR (see, for example, EP 239400, EP 125023, WO 90 / 07861, and WO 96 / 02576). The variable region of an antibody typically consists of three CDRs sandwiched between four FRs. CDRs are the regions that essentially determine the binding specificity of an antibody. While the amino acid sequences of CDRs are highly diverse, the amino acid sequences constituting the FRs often show high homology or identity even between antibodies with different binding specificities. Therefore, it is generally believed that CDR grafting can transfer the binding specificity of one antibody to another. Furthermore, from the viewpoint of maintaining the function of the CDR, when grafting a non-human CDR onto a human FR, a human FR having high homology or identity to the non-human animal-derived FR is selected. That is, since the amino acids in the CDR not only recognize the antigen but also coordinate with the amino acids in the FR adjacent to the CDR and are involved in maintaining the loop structure of the CDR, it is preferable to use a human FR having an amino acid sequence having high homology or identity to the amino acid sequence of the FR adjacent to the CDR to be grafted.
[0075] A search for known human FRs that are highly homologous or identical to non-human animal-derived FRs can be performed, for example, using an antibody-specific search system available on the Internet (http: / / www.bioinfo.org.uk / abysis / ). Mutations can be introduced into sequences other than the CDRs of the non-human antibody so that they match the sequence of the human FR obtained in this manner. Alternatively, if a gene (cDNA) encoding the amino acid sequence of the human FR obtained by the search is available, the non-human CDRs can be introduced into that sequence. Introduction of mutations, etc., can be performed using techniques known in the art, such as nucleic acid synthesis and site-directed mutagenesis.
[0076] By qualitatively or quantitatively measuring and evaluating the antigen-binding activity of the humanized antibody thus prepared, it is possible to suitably select FRs of a human-derived antibody that form a good antigen-binding site when linked via the CDRs. Furthermore, if necessary, amino acid residues in the FRs can be substituted so that the CDRs of the humanized antibody form a suitable antigen-binding site, according to the method described in Sato, K. et al., Cancer Res, 1993, 53, 851-856, etc., and mutant FR sequences with desired properties can be selected by measuring and evaluating the antigen-binding activity of mutant antibodies with the amino acid substitutions.
[0077] Furthermore, the antibody of the present invention may also be an antibody that competes for binding to HLA-DR with an antibody having a variable region or CDR containing the above-mentioned specific amino acid sequence or a variant thereof. In other words, the antibody may be an antibody that binds to an epitope to which an antibody having a variable region or CDR containing the above-mentioned specific amino acid sequence or a variant thereof exhibits binding affinity.
[0078] In the present invention, the term "epitope" refers to an antigenic determinant present in an antigen, i.e., a site on an antigen to which an antigen-binding domain in an antibody binds. Therefore, an epitope in the present invention may be a polypeptide consisting of multiple consecutive amino acids in the primary amino acid sequence (linear epitope), or a polypeptide formed when non-adjacent amino acids in the primary amino acid sequence are brought into close proximity due to a three-dimensional structure such as peptide or protein folding (discontinuous epitope, structural epitope). Furthermore, such epitopes typically consist of at least three (e.g., four), and most usually at least five (e.g., 6-20, 7-15, 8-10) amino acids.
[0079] Furthermore, once an antibody is obtained, a person skilled in the art can identify the peptide region (epitope) on the antigen to which the antibody is reactive and prepare various antibodies that bind to that peptide region. Furthermore, whether two antibodies bind to the same or sterically overlapping epitopes can be determined by a competitive assay.
[0080] In the present invention, the term "functional fragment" of an antibody refers to a portion (partial fragment) of an antibody that recognizes HLA-DR. Specific examples include Fab, Fab', F(ab')2, variable region fragments (Fv), disulfide-linked Fv, single-chain variable region fragments (single-chain Fv, scFv), sc(Fv)2, and polymers thereof.
[0081] As used herein, "Fab" refers to a monovalent antigen-binding fragment of an immunoglobulin consisting of one light chain and part of a heavy chain. It can be obtained by papain digestion of an antibody or by recombinant methods. "Fab'" differs from Fab by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain, including one or more cysteines in the antibody hinge region. "F(ab')2" refers to a bivalent antigen-binding fragment of an immunoglobulin consisting of both light chains and part of both heavy chains.
[0082] A "variable region fragment (Fv)" is the smallest antibody fragment that has a complete antigen recognition and binding site. Fv is a dimer in which a heavy chain variable region and a light chain variable region are tightly linked by non-covalent bonds. A "single-chain variable region fragment (single-chain Fv, scFv)" contains an antibody's heavy chain variable region and light chain variable region, and these regions are present in a single polypeptide chain. An "sc(Fv)2" is a single chain formed by linking two heavy chain variable regions and two light chain variable regions with a linker or the like.
[0083] The antibodies of the present invention can be produced by the hybridoma method or by recombinant DNA technology. A representative example of the hybridoma method is the method of Kohler and Milstein (Kohler & Milstein, Nature, 256:495 (1975)). The antibody-producing cells used in the cell fusion step in this method are spleen cells, lymph node cells, peripheral blood leukocytes, etc. of animals (e.g., mice, rats, hamsters, rabbits, monkeys, goats) immunized with an antigen (HLA-DR, its partial peptides, proteins in which HLA-DR is fused with Fc protein or the like, or cells expressing these, etc.). Antibody-producing cells obtained by reacting the antigen in a culture medium with the above-mentioned cells or lymphocytes, etc., previously isolated from an unimmunized animal can also be used. Various known cell lines can be used as myeloma cells. The antibody-producing cells and myeloma cells may be derived from different animal species, as long as they are fusible, but are preferably derived from the same animal species. Hybridomas are produced, for example, by cell fusion between spleen cells obtained from a mouse immunized with an antigen and mouse myeloma cells, and then hybridomas producing monoclonal antibodies that recognize HLA-DR can be obtained by screening. Monoclonal antibodies that recognize HLA-DR can be obtained by culturing hybridomas or from the ascites of a mammal to which the hybridoma has been administered.
[0084] The recombinant DNA method involves cloning DNA encoding the antibody of the present invention from hybridomas, B cells, or the like, incorporating it into an appropriate vector, and then introducing it into host cells (e.g., mammalian cell lines such as HEK cells, Escherichia coli, yeast cells, insect cells, plant cells, etc.) to produce the antibody of the present invention as a recombinant antibody (e.g., P. J. Delves, Antibody Production: Essential Techniques, 1997 WILEY, P. Shepherd and C. Dean Monoclonal Antibodies, 2000 OXFORD UNIVERSITY PRESS; Vandamme A. M. et al., Eur. J. Biochem. 192:767-775 (1990)). In expressing DNA encoding the antibody of the present invention, DNA encoding the heavy chain and DNA encoding the light chain may be separately incorporated into expression vectors and used to transform host cells, or DNA encoding the heavy chain and DNA encoding the light chain may be incorporated into a single expression vector and used to transform host cells (see WO 94 / 11523). The antibody of the present invention can be obtained in a substantially pure and homogeneous form by culturing the host cells and isolating and purifying it from within the host cells or from the culture medium. Antibody isolation and purification can be performed using methods commonly used for purifying polypeptides. By using transgenic animal production techniques to produce transgenic animals (such as cows, goats, sheep, and pigs) incorporating antibody genes, it is possible to obtain large quantities of monoclonal antibodies derived from the antibody genes from the milk of the transgenic animals.
[0085] The present invention can also provide DNA encoding the antibody of the present invention, a vector containing the DNA, a host cell harboring the DNA, and a method for producing the antibody, comprising culturing the host cell and recovering the antibody.
[0086] <Chimeric Antigen Receptor> As shown in the Examples below, HLA-DR, which is the target of the antibody of the present invention, is a cell surface antigen specific to blood cancer. Furthermore, the variable regions of the antibody of the present invention are useful in chimeric antigen receptors (CARs) and T cells expressing the same (so-called CAR-Ts). Thus, the present invention may also take the form of a CAR comprising an antibody that binds to HLA-DR or its variable region, a transmembrane domain, and an intracellular signal domain.
[0087] In the present invention, the term "chimeric antigen receptor (CAR)" refers to a chimeric protein in which an HLA-DR-binding domain serving as an extracellular domain, a transmembrane domain, and an intracellular signal domain are arranged in this order from the N-terminus and linked directly or indirectly.
[0088] In the present invention, the "region that binds to HLA-DR (antigen-binding region)" can be, for example, the above-mentioned antibody or a functional fragment thereof, and typically, an scFv is used for a CAR.
[0089] As described above, an "scFv" is a structure in which the light chain variable region and heavy chain variable region of a monoclonal antibody (immunoglobulin) are linked via a linker, and retains antigen-binding ability. The order of the N-terminal end of the scFv may be the light chain variable region, linker, and heavy chain variable region, or the heavy chain variable region, linker, and light chain variable region.
[0090] As the "linker" in scFv, for example, a peptide linker can be used. The length of the linker is not particularly limited. For example, a linker containing 5 to 25 amino acids can be used. The length of the linker is preferably 8 to 25 amino acids, more preferably 15 to 20 amino acids. Suitable examples of peptide linkers include peptide linkers containing glycine or glycine and serine (GGS linker, GS linker, GGG linker, Whitlow / 218 linker, etc.). Glycine and serine, which are amino acids constituting these linkers, have the advantage that they are small in size and are less likely to form higher-order structures within the linker.
[0091] The monoclonal antibody that serves as the basis for the scFv is not particularly limited, and examples thereof include the above-mentioned antibodies derived from non-human animals, human antibodies, and humanized antibodies. Preferred examples are also as described above.
[0092] In the present invention, the "transmembrane region" is not particularly limited as long as it is a polypeptide that has the function of penetrating a cell membrane and can anchor a CAR to the cell membrane. Examples of proteins from which polypeptides carrying a transmembrane region are derived include CD28, CD3ζ, CD3ε, 4-1BB, CD45, CD4, CD5, CD8α, CD8β, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, ICOS, CD154, GITR, and the α chain and β chain of a T cell receptor.
[0093] In the present invention, the "intracellular signaling region" refers to a region that is located intracellularly when the CAR is located on the cell membrane, and is capable of transmitting a signal required for immune cell effector function, i.e., a region that is capable of transmitting a signal required for immune cell activation (a so-called primary signal) when the antigen-binding region binds to an antigen (HLA-DR). Such intracellular signaling regions generally include those that have only an activation signaling domain such as a T cell receptor (TCR) and CD3 complex (first-generation CARs), those that have an activation signaling domain plus a costimulatory signaling domain derived from a costimulatory molecule (e.g., the intracellular domain of CD28 or 4-1BB) (second-generation CARs), and those that have an activation signaling domain plus multiple costimulatory signaling domains (e.g., the intracellular domains of CD28 and 4-1BB) (third-generation CARs). Further examples include those that contain a CD79A intracellular region and a CD40 intracellular region (see Mol Ther 2021 Sep 1;29(9):2677-2690).
[0094] As described above, the "intracellular signaling region" may be any region capable of transmitting a primary signal, and an activation signaling domain of a protein involved in the signal can be used. Primary signaling is known to involve immunoreceptor tyrosine-based activation motifs (ITAMs). Examples of proteins having ITAMs include CD3ζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, CD66d, DAP10, and DAP12.
[0095] In the present invention, the number of intracellular signal regions contained in a CAR is not limited to one, and the CAR may contain multiple intracellular signal regions (for example, 1 to 5, 1 to 3, or 1 or 2 signal transduction factors). In this case, the multiple intracellular signal regions contained may be the same or different.
[0096] The CAR of the present invention may comprise other domains in addition to the above-mentioned antigen-binding domain, transmembrane domain, and intracellular signal domain. Examples of other domains include, but are not limited to, a costimulatory signaling domain, a spacer sequence, a signal peptide, etc.
[0097] It is known that costimulatory molecules expressed on T cells transmit costimulatory signals intracellularly upon binding to ligands specific to each costimulatory molecule expressed on antigen-presenting cells, thereby assisting T cell activation (secondary signaling). In the present invention, a "costimulatory transmission region" refers to an intracellular domain involved in the costimulatory signal transmission of the above-mentioned costimulatory molecules. Examples of costimulatory molecules include CD28, 4-1BB (CD137), OX40 (CD134), ICOS, CD2, CD4, CD5, CD8α, CD8β, CD154, and the like. The CAR of the present invention can comprise the costimulatory transmission region of these costimulatory molecules.
[0098] The number of costimulatory signaling regions that the CAR of the present invention can comprise is not limited to one, and may be more than one. The CAR of the present invention can comprise, for example, 1 to 5, 1 to 3, or 1 or 2 costimulatory signaling regions. When the CAR of the present invention comprises more than one costimulatory signaling region, the regions may be the same or different.
[0099] In the present invention, the term "spacer" refers to a sequence that links each region, etc., and is not particularly limited as long as it does not inhibit the function of each region. The number of amino acids therein is also not particularly limited, but it is usually 1 to 500 amino acids, preferably 5 to 300 amino acids, and more preferably 10 to 100 amino acids.
[0100] The spacer sequence is not particularly limited, and examples of spacer sequences that can be used include the hinge region or a portion thereof of IgG, preferably human IgG (e.g., subtypes IgG1 and IgG4), the hinge region and a portion of CH2, or a portion of a factor used in a transmembrane domain (e.g., CD28). Utilizing the sequence of the hinge region or a portion thereof is expected to result in a highly flexible spacer.
[0101] In the present invention, the term "signal peptide" refers to a peptide that promotes the secretion of a CAR or directs its localization to the cell membrane, and is also referred to as a leader sequence. The signal peptide can usually be directly or indirectly bound to the N-terminus of the antigen-binding region. Optionally, the signal peptide may be cleaved from the antigen-binding region during cellular processing and localization of the CAR to the cell membrane. Examples of such signal peptides include signal peptides of immunoglobulins (such as IgK), human GM-CSF receptor, the α and β chains of T-cell receptor, CD8α, CD8β, CD3ζ, CD28, CD3ε, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, ICOS, CD154, GITR, and the like.
[0102] Examples of each region, etc. in the CAR of the present invention have been described above. However, those skilled in the art can appropriately obtain specific amino acid sequences of these regions, etc. by searching known literature or databases such as NCBI (http: / / www.ncbi.nlm.nih.gov / guide / ). Specific sequences are also disclosed in the sequence listing of the present application. Furthermore, the regions, etc. of the present invention are not limited to such typical amino acid sequences (e.g., NCBI reference sequences), and may also include variants and homologs of these typical amino acid sequences, so long as the functions of the regions are maintained. Furthermore, such variants and homologs usually have high homology or identity to the typical amino acid sequences. High homology or identity is usually 60% or more, preferably 70% or more, more preferably 80% or more, and even more preferably 90% or more (e.g., 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more).
[0103] The CAR of the present invention may be a molecule consisting of one type of polypeptide or a molecule consisting of a complex of two or more types of polypeptides.The CAR of the present invention may be a molecule consisting of a polypeptide or a complex thereof, or may be a molecule formed by linking another substance (e.g., a fluorescent substance, a radioactive substance, an inorganic particle, etc.) to a polypeptide or a complex thereof.
[0104] The CAR of the present invention may be chemically modified. The polypeptide constituting the CAR of the present invention may have a C-terminus that is a carboxyl group (—COOH), a carboxylate (—COO—), an amide (—CONH 2or an ester (-COOR). Here, examples of R in the ester include a C1-6 alkyl group such as methyl, ethyl, n-propyl, isopropyl, and n-butyl; a C3-8 cycloalkyl group such as cyclopentyl and cyclohexyl; a C6-12 aryl group such as phenyl and α-naphthyl; a phenyl-C1-2 alkyl group such as benzyl and phenethyl; a C7-14 aralkyl group such as an α-naphthyl-C1-2 alkyl group such as α-naphthylmethyl; and a pivaloyloxymethyl group. In the polypeptide constituting the CAR of the present invention, a carboxyl group (or carboxylate) other than the C-terminus may be amidated or esterified. In this case, the above-mentioned C-terminal esters, etc., are used as the ester. Furthermore, the polypeptide constituting the CAR of the present invention also includes one in which the amino group of the N-terminal amino acid residue is protected with a protecting group (e.g., a C1-6 acyl group such as a formyl group or a C1-6 alkanoyl group such as an acetyl group), one in which the N-terminal glutamine residue that can be generated by cleavage in vivo is pyroglutamated, and one in which a substituent on the side chain of an amino acid in the molecule (e.g., —OH, —SH, an amino group, an imidazole group, an indole group, a guanidino group, etc.) is protected with an appropriate protecting group (e.g., a C1-6 acyl group such as a formyl group or a C1-6 alkanoyl group such as an acetyl group).
[0105] Furthermore, the CAR of the present invention may have another functional protein. The other functional protein is not particularly limited and may be appropriately selected depending on the function to be imparted to the CAR of the present invention. For example, functional proteins used for the purpose of facilitating the purification and detection of the CAR include Myc tag, His tag, HA tag, FLAG tag (registered trademark, Sigma-Aldrich), fluorescent protein tag (GFP, etc.), etc.
[0106] The chimeric antigen receptor of the present invention may be in the form of a pharmaceutically acceptable salt with an acid or base. The salt is not particularly limited as long as it is pharmaceutically acceptable, and both acidic and basic salts can be used. Examples of acidic salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, nitrate, and phosphate; organic acid salts such as acetate, propionate, tartrate, fumarate, maleate, malate, citrate, methanesulfonate, and paratoluenesulfonate; and amino acid salts such as aspartate and glutamate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt. The chimeric antigen receptor of the present invention may be in the form of a solvate. The solvent is not particularly limited as long as it is pharmaceutically acceptable, and examples include water, ethanol, glycerol, and acetic acid.
[0107] There have been several reports of experiments and clinical studies using CAR (e.g., Rossig C, et al. Mol Ther 10:5-18, 2004; Dotti G, et al. Hum Gene Ther 20:1229-1239, 2009; Ngo MC, et al. Hum Mol Genet 20(R1):R93-99, 2011; Ahmed N, et al. Mol Ther 17:1779-1787, 2009; Pulé MA, et al. Nat Med 14:1264-1270, 2008; Louis CU, et al. Blood 118:6050-6056, 2011; Kochenderfer JN, et al. Blood 116:4099-4102, 2010; Kochenderfer JN, et al. Blood 119:2709-2720, 2012; Porter DL, et al. N Engl J Med365:725-733, 2011; Kalos M, et al. Sci Transl Med 3:95ra73, 2011; Brentjens RJ, et al. Blood 118:4817-4828, 2011; Brentjens RJ, et al. SciTransl Med 5:177 ra38, 2013), the CAR of the present invention can be constructed by referring to these reports. In addition, since specific sequences and the like are also shown in the Examples described later, the CAR of the present invention can also be constructed by referring to these.
[0108] <Nucleotides encoding chimeric antigen receptors> The present invention provides polynucleotides encoding the CARs of the present invention. Information on the nucleotide sequence encoding the antigen-binding region such as scFv can be obtained, for example, by analyzing the nucleotide sequence of a hybridoma producing the monoclonal antibody on which the CAR is based.
[0109] Furthermore, specific nucleotide sequences encoding each region, etc., of the CAR of the present invention other than the antigen-binding region can be appropriately obtained by those skilled in the art by searching known literature or databases such as NCBI (http: / / www.ncbi.nlm.nih.gov / guide / ). Furthermore, the nucleotide sequences encoding the above regions, etc. are not limited to known ones, and any nucleotide sequence encoding the above regions, etc. can be used. Due to the degeneracy of the genetic code, there are multiple codons corresponding to one amino acid. Therefore, there are many nucleotide sequences encoding the same amino acid sequence. The nucleotide sequence of the polynucleotide of the present invention may be any of multiple nucleotide sequences resulting from the degeneracy of the genetic code, as long as it encodes the CAR of the present invention. Furthermore, in order to optimize expression in cells expressing a CAR, the codons selected to encode an amino acid in the nucleotide sequence encoding each region, etc., of the CAR of the present invention may be modified.
[0110] Based on such nucleotide sequence information, a person skilled in the art can prepare polynucleotides encoding each region, etc., using known techniques such as chemical synthesis (such as the phosphoramidite method) or PCR amplification. Furthermore, a polynucleotide encoding the CAR of the present invention can be obtained by ligating the thus obtained polynucleotides encoding each region, etc., directly or via a spacer. Note that ligation of polynucleotides encoding each region, etc. can be carried out using known methods such as overlap extension PCR, as shown in the Examples described later.
[0111] <Vector Comprising a Polynucleotide Encoding a Chimeric Antigen Receptor> The present invention provides a vector comprising the above-described polynucleotide. The vector of the present invention may be linear or circular, and examples thereof include viral vectors, plasmid vectors, episomal vectors, artificial chromosome vectors, and transposon vectors.
[0112] Examples of viral vectors include retroviral vectors such as lentivirus, Sendai virus vectors, adenovirus vectors, adeno-associated virus vectors, herpes virus vectors, vaccinia virus vectors, poxvirus vectors, poliovirus vectors, Sindbis virus vectors, rhabdovirus vectors, paramyxovirus vectors, and orthomyxovirus vectors.
[0113] Examples of the plasmid vector include plasmid vectors for expression in animal cells, such as pcDNA3.1, pA1-11, pXT1, pRc / CMV, pRc / RSV, and pcDNAI / Neo.
[0114] An episomal vector is a vector capable of autonomous replication outside of a chromosome. Specific means for using an episomal vector are known (see Yu et al., Science, 2009, 324, pp. 797-801). Examples of episomal vectors include vectors that contain, as vector elements, sequences necessary for autonomous replication derived from EBV, SV40, etc. Specific examples of vector elements necessary for autonomous replication include a replication origin and a gene encoding a protein that binds to the replication origin and controls replication, such as the replication origin oriP and EBNA-1 gene for EBV, and the replication origin ori and SV40LT gene for SV40.
[0115] Examples of artificial chromosome vectors include YAC (Yeast artificial chromosome) vectors, BAC (Bacterial artificial chromosome) vectors, and PAC (P1-derived artificial chromosome) vectors.
[0116] Of these vectors, retroviral vectors are preferred from the viewpoint that they can easily transfer genes efficiently even into cells that grow slowly, and that stable expression strains can be easily established.
[0117] The vector of the present invention may include, in addition to the above-described polynucleotide encoding a CAR, an expression control sequence such as a promoter, an enhancer, a poly A addition signal, or a terminator, a nucleotide sequence encoding a replication origin or a protein that binds to the replication origin to control replication, nucleotides encoding other proteins, and the like.
[0118] The polynucleotide encoding the above-mentioned CAR and nucleotides encoding other proteins described below can be operably positioned downstream of a promoter to enable efficient transcription of each polynucleotide. Examples of such "promoters" include a CMV (cytomegalovirus) promoter, an SRα promoter, an SV40 early promoter, a retroviral LTR, an Rous sarcoma virus (RSV) promoter, an HSV-TK (herpes simplex virus thymidine kinase) promoter, an EF1α promoter, a metallothionein promoter, and a heat shock promoter.
[0119] Examples of "nucleotides encoding other proteins" include marker genes such as fluorescent protein genes, reporter genes, and drug resistance genes, and genes encoding molecules involved in T cell activation, such as cytokines. Further examples include EGFR without an intracellular domain (truncated EGFR, tEGFR), as shown in the Examples below. Furthermore, by using DNA encoding an IRES or a 2A peptide sequence (e.g., 2A peptide (T2A) derived from Thosea asigna), the other proteins can be expressed polycistronically together with the above-mentioned CAR.
[0120] Furthermore, in order to appropriately induce apoptosis of the administered CAR-expressing cells in the body of a subject (e.g., a patient with blood cancer) to which the CAR-expressing cells have been administered, the vector of the present invention may contain a suicide gene as a "nucleotide encoding another protein." Examples of suicide genes include herpes simplex virus thymidine kinase (HSV-TK) and inducible caspase 9 (iCasp9). Examples of drugs that activate the functions of such genes include ganciclovir for HSV-TK and AP1903, a chemical induction of dimerization (CID) compound for iCasp9 (Cooper LJ. et al., Cytotherapy. 2006; 8(2): pp. 105-17; Jensen M.C. et al., Biol Blood Marrow Transplant. 2010 Sep; 16(9): pp. 1245-56; Jones B.S., Front Pharmacol. 2014 Nov 27; 5: 254; Minagawa K., Pharmaceuticals (Basel). 2015 May 8;8(2):230-49; Bole-Richard E., Front Pharmacol. 2015 Aug 25;6:174).
[0121] <Cells expressing chimeric antigen receptors> The present invention provides cells expressing the CAR of the present invention. The cells of the present invention can be obtained by introducing into a cell a polynucleotide or vector encoding the above-described CAR of the present invention.
[0122] The "cells" into which the polynucleotide or vector of the present invention is introduced are preferably mammalian-derived cells, and for example, human-derived cells or cells derived from non-human mammals such as rodents (mouse, rat, etc.), cattle, sheep, horses, dogs, pigs, and monkeys can be used. The type of cells is not particularly limited, and cells collected from body fluids such as blood and bone marrow fluid, tissues such as the spleen, thymus, and lymph nodes, tumors, cancerous ascites, etc. can be used. A preferred example of a CAR-expressing cell is an immune cell.
[0123] Examples of "immune cells" include CD4-positive CD8-negative T cells, CD4-negative CD8-positive T cells, T cells, αβ-T cells, γδ-T cells, NK cells, NKT cells, and the like. Such immune cells include those prepared from pluripotent stem cells such as iPS cells. Furthermore, various cell populations can be used as long as they contain lymphocytes or progenitor cells as described above. That is, PBMCs (peripheral blood mononuclear cells) collected from peripheral blood are also an example of immune cells.
[0124] The CAR-expressing cells may be activated before introduction of the polynucleotide of the present invention. For example, the CAR-expressing cells can be activated by stimulation with an anti-CD3 antibody and an anti-CD28 antibody. More specifically, stimulation with the anti-CD3 antibody and the anti-CD28 antibody can be added by culturing the cells in a culture vessel (e.g., a culture dish) whose culture surface has been coated with the anti-CD3 antibody and the anti-CD28 antibody. Such stimulation can also be performed using magnetic beads coated with the anti-CD3 antibody and the anti-CD28 antibody (e.g., Dynabeads T-Activator CD3 / CD28 provided by VERITAS).
[0125] Furthermore, as shown in the Examples below, in order to prevent exhaustion of the cells of the present invention, a tyrosine kinase inhibitor, such as dasatinib, may be added to the culture medium during the production of the cells.
[0126] In order to increase the cell survival rate / proliferation rate, a culture medium supplemented with a T cell growth factor may be used during activation treatment. IL-2, IL-15, IL-7, etc. can be used as the T cell growth factor. IL-2, IL-15, IL-7, etc. can be prepared according to standard methods. Commercially available products can also be used. While the use of T cell growth factors from animal species other than humans is not excluded, typically, T cell growth factors derived from humans (which may be recombinant) are used.
[0127] Typically, for application (administration to a subject), cells after introduction of the polynucleotide of the present invention are grown. For example, the cells into which the polynucleotide of the present invention has been introduced are cultured (subcultured as necessary) using a culture medium supplemented with a T cell growth factor. In addition to this culture, a treatment (reactivation) similar to that used in the activation of cells for expressing CAR may be performed.
[0128] Although a medium containing serum (human serum, fetal bovine serum, etc.) may be used to culture the cells of the present invention, the use of a serum-free medium makes it possible to prepare cells that are highly safe for clinical application and have the advantage of being less susceptible to differences in culture efficiency due to differences between serum lots. When serum is used, it is preferable to use autologous serum, i.e., serum collected from the subject who will receive the cells of the present invention.
[0129] Furthermore, the cells of the present invention may be cells in which the function of a protein (such as an immune checkpoint substance) that suppresses excessive immune responses, etc., is suppressed. Examples of such proteins include Programmed Death 1 (PD-1), PD-L1, PD-L2, CTLA-4, TIM-3, CEACAM (such as CEACAM-1, CEACAM-3, and CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, and GAL9.
[0130] Furthermore, the cells of the present invention may be cells in which the functions of endogenous proteins such as TCR and HLA are suppressed in order to facilitate allogeneic transplantation.
[0131] Methods for suppressing the function of a protein include knockout methods that target the gene encoding the protein, methods that use dsRNA (double-stranded RNA, for example, siRNA) complementary to the transcription product of the gene, methods that use antisense RNA complementary to the transcription product, and methods that use RNA with ribozyme activity that specifically cleaves the transcription product. In addition, genome editing methods, which are methods that use site-specific nucleases (e.g., zinc finger nucleases (ZFNs), transcription activation-like effector nucleases (TALENs), DNA double-strand cleavage enzymes such as CRISPR-Cas9) to modify target genes, are also suitable for suppressing the function of the substance.
[0132] Methods for introducing the polynucleotide or vector of the present invention into cells include lipofection, microinjection, calcium phosphate, DEAE-dextran, electroporation, and particle gun methods. Furthermore, when the vector of the present invention is a retroviral vector, appropriate packaging cells may be selected based on the LTR sequence and packaging signal sequence contained in the vector, and used to prepare retroviral particles. Examples of packaging cells include PG13, PA317, GP+E-86, GP+envAm-12, and Psi-Crip. Furthermore, 293 cells and 293T cells, which have high transfection efficiency, can also be used as packaging cells.
[0133] Furthermore, after the polynucleotide or vector of the present invention is introduced into a cell, the expression of CAR in the cell can be confirmed by a known method such as flow cytometry, RT-PCR, Northern blotting, Western blotting, ELISA, or fluorescent immunostaining.
[0134] <Multispecific antibodies> As will be described in the Examples below, HLA-DR, the target of the antibody of the present invention, is a cell surface antigen specific to blood cancer. Therefore, if immune cells can be directed to blood cancer cells using this antigen as a marker and cytotoxicity or the like can be achieved, this will contribute to the treatment of these diseases. One embodiment that makes such immunotherapy possible is a multispecific antibody.
[0135] "Multispecific antibody" means a monoclonal antibody that possesses multiple antigen recognition sites and has binding specificities for at least two different antigens.
[0136] In the present invention, a multispecific antibody comprises the above-described antibody of the present invention or a functional fragment thereof and an antigen recognition site on an immune cell. Such immune cells are not particularly limited and are as exemplified above in <Cells expressing chimeric antigen receptors>, but are preferably effector cells from the viewpoint of their ability to cause cytotoxicity or the like on target cells such as blood cancer cells. Examples of effector cells include NK (natural killer) cells, monocytes, macrophages, eosinophils, etc. Furthermore, antigens that can be recognized by the multispecific antibodies of the present invention in such cells include stimulatory or inhibitory receptors present on the surface of the cells. More specifically, examples include CD3, CD16, B7-H4, BTLA, CD4, CD8, CD25, CD27, CD28, CD32, CD56, CD137, CTLA-4, GITR, HVEM, ICOS, LAG-3, NKG2D, OX40, PD-1, TIGIT, TIM-3, VISTA, 4-1BB, NK-expressing KIR, B7-1, B7-2, B7H3, PD-L1, PD-L2, and TNFSF9.
[0137] Preferred embodiments of the multispecific antibodies of the present invention include bispecific antibodies, and more specific examples include BsDb (bispecific diabody), scBsDb (single-chain bispecific diabody), scBsTaFv (single-chain bispecific tandem variable domain), DNL-(Fab)3 (dock-and-lock trivalent Fab), sdAb (single domain antibody), BssdAb (double single-chain complex antibody), Knobs-into-holes BsAb IgG, Ig-scFv fusion type, Diabody-Fc fusion type, and dual variable region antibody (DVD-IgG).
[0138] Furthermore, such bispecific antibodies can be prepared by those skilled in the art using appropriate known techniques. Examples of such known techniques include a method (quadroma method) in which a hybridoma producing an antibody that recognizes HLA-DR and a hybridoma producing an antibody that recognizes immune cells are further fused to produce bispecific antibodies from the fused cells. Another example is a method in which functional fragments (e.g., Fab) of these different antibodies are chemically crosslinked. Another example is a method in which DNAs encoding functional fragments of these different antibodies are fused via a linker, the resulting DNA construct is introduced into host cells, and the antibodies are produced from the cells. Furthermore, Knob-into-Hole (Genentech), Triomab / Quadroma (Trion Pharma / Fresenius Biotech), CrossMAb (Roche), electrostatic-matched (Amgen), LUZ-Y (Genentech), Strand Exchange Engineered Domain body (SEEDbody) (EMD Serono), Biclonic (Merus) Duo methods for promoting heterodimerization of different antibodies or functional fragments thereof, such as the Fab-Body (GenmabA / S); the controlled Fab-ARM exchange method (CFAF method) described in WO 2008 / 119353, WO 2011 / 131746, etc.; the Generation and Characterization of a Dual Variable Domain Immunoglobulin (DVD-Ig) method described by Chengbin Wu et al.;TM ) Molecule, Springer Nature Experiments, 2010.
[0139] <Antibody-drug conjugate> As shown in the examples below, HLA-DR, which is the target of the antibody of the present invention, is a cell surface antigen specific to blood cancer. Therefore, the present invention can also take the form of an antibody-drug conjugate (ADC) comprising an antibody of the present invention (particularly a humanized antibody) or a functional fragment thereof conjugated to a drug.
[0140] In the ADC of the present invention, the "drug" that can be conjugated to the antibody is not particularly limited, and examples include cytotoxic substances known in the art. Examples of "cytotoxic substances" include anticancer agents, for example, irinotecan (CPT-11), irinotecan metabolite SN-38 (10-hydroxy-7-ethylcamptothecin), alkylating agents such as adriamycin, taxol, 5-fluorouracil, nimustine, laministine, and temozolomide, antimetabolites such as gemcitabine and hydroxycarbamide, plant alkaloids such as etoposide and vincristine, anticancer antibiotics such as mitomycin and bleomycin, platinum preparations such as cisplatin, molecular targeted agents such as sorafenib and erlotinib, methotrexate, cytosine arabinoside, 6-thioguanine, 6-mercaptopurine, cyclophosphamide, ifosfamide, busulfan, MMAE (monomethylauristatin E), DM1 (mertansine), and calicheamicin. Cytotoxic agents include radioisotopes, e.g., 32 P. 14 C. 125 I, 3 H. 131 I, 186 Re, 188 Re, 10 B. 111 In, 90Y can also be mentioned. Cytotoxic substances may be photosensitive substances that exert cytotoxic activity, more specifically, substances that are activated by light irradiation and change into a form that exhibits cytotoxicity (cytotoxicity) themselves, or substances that produce cytotoxic substances (cytotoxic substances). Examples include chlorins, chlorin e6, porfimer sodium, talaporfin sodium, verteporfin, and precursors and derivatives thereof. Cytotoxic substances also include toxic peptides, such as ribosome-inactivating proteins (RIPs) such as saporin, ricin, and Shiga poison.
[0141] Furthermore, the binding of an antibody to a cytotoxic substance can be carried out by a method known in the art, and may be either direct or indirect. For example, a covalent bond can be used for direct binding. For indirect binding, binding via a linker can be used. General techniques for linkers are described, for example, in Hermanson, G. T., Bioconjugate Techniques, Academic Press, 1996; Harris, J. M. and Zalipsky, S. (eds.), Poly(ethylene glycol), Chemistry and Biological Applications, ACS Symposium Series, 1997; Veronese, F. and Harris, J. M., Bioconjugate Techniques, Academic Press, 1996; Peptide and protein PEGylation, Advanced Drug Delivery Review 54(4), 2002. The linker may be a linear linker (divalent linker) or a branched linker (trivalent or higher linker).
[0142] <Pharmaceutical Compositions> The present invention also provides pharmaceutical compositions (e.g., anticancer agents) containing as an active ingredient the antibody of the present invention or a variable region thereof, or an antibody construct carrying the antibody or variable region thereof (such as the above-mentioned cells expressing a chimeric antigen receptor, a multispecific antibody, or an antibody-drug conjugate (ADC); hereinafter, also simply referred to as "the antibody of the present invention, etc."), as well as methods for treating diseases (e.g., blood cancers such as acute myeloid leukemia) comprising the step of administering a therapeutically effective amount of the antibody of the present invention, etc. to a subject.
[0143] The "disease" targeted by the present invention is not particularly limited as long as it is a disease associated with cells that retain HLA-DR as a specific surface antigen, and examples thereof include blood cancers, and more specifically, acute myeloid leukemia and its related diseases (myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL), B-cell malignant lymphoma, multiple myeloma, etc.). "Blood cancer" may be a primary cancer, a recurrent cancer, a secondary cancer, or a metastatic cancer. "Acute myeloid leukemia (AML)" refers to a diverse blood tumor characterized by the autonomous clonal proliferation of immature myeloid cells with impaired differentiation and maturation ability. AML is also a myeloid lineage cancer of blood cells characterized by the rapid proliferation of abnormal leukemic cells in the bone marrow and the consequent significant inhibition of normal hematopoietic function, and presents with symptoms associated with leukopenia, anemia, thrombocytopenia, etc.
[0144] The "pharmaceutical composition" of the present invention may contain, in addition to the antibody of the present invention, other pharmacologically acceptable components. Examples of such other components include carriers, emulsifiers, humectants, pH buffering agents, culture media, excipients, disintegrants, buffers, isotonicity agents, suspending agents, solubilizers, soothing agents, stabilizers, preservatives, and antiseptics. More specifically, in the case of liquid preparations such as injections, examples of pharmacologically acceptable other components include aqueous solutions (e.g., physiological saline, water for injection, phosphate buffer, aqueous glucose solution, aqueous glycerol solution), and aluminum hydroxide. In the case of lyophilized preparations, examples include, but are not limited to, sugars (e.g., mannitol, lactose, saccharose), albumin, and the like. Furthermore, the pharmaceutical composition of the present invention may be in the form of a kit in which the above components can be mixed prior to administration. Furthermore, when used as an injection, the composition may be in the form of a syringe.
[0145] The pharmaceutical composition of the present invention may contain only the antibody, etc. of the present invention as an active ingredient, or may contain the antibody, etc. and at least one other anticancer agent. The antibody, etc. of the present invention can also be administered together with other anticancer agents, thereby enhancing the antitumor effect. The other anticancer agents used for such purposes may be administered to a subject simultaneously with the antibody, etc. of the present invention, separately, or consecutively, or may be administered at different administration intervals. Examples of such "anticancer drugs" include venetoclax, azacitidine, dasatinib, cytarabine (Ara-C, Cytosar-U), enocitabine, quizartinib (AC220), sorafenib (BAY 43-906), lestaurtinib (CEP-701), midostaurin (PKC412), carboplatin, carmustine, chlorambucil, dacarbazine, ifosfamide, lomustine, mechlorethamine, procarbazine, pentostatin, (2' deoxycoformycin), etoposide, teniposide, topotecan, vinblastine, vincristine, paclitaxel, dexamethasone, methylprednisolone, prednisone, all-trans retinoic acid, arsenic trioxide, interferon α, rituximab (Rituxan®), gemtuzumab ozogamicin, imatinib mesylate, citosar-U, melphalan, busulfan (Myleran®), thiotepa, bleomycin, protease inhibitors Examples of such antitumor agents include Latina (cisplatin), cyclophosphamide, Cytoxan (registered trademark), daunorubicin, doxorubicin, idarubicin, mitoxantrone, 5-azacytidine, cladribine, fludarabine, hydroxyurea, 6-mercaptopurine, methotrexate, 6-thioguanine, immune checkpoint inhibitors (anti-PD-1 antibodies, etc.), and any combination thereof, but are not limited thereto as long as they have antitumor activity. Furthermore, the pharmaceutical composition of the present invention, the antibody of the present invention, etc. may be used in combination with other cancer treatment methods, such as radiotherapy and cancer immunotherapy, as well as chemotherapy using the aforementioned anticancer agents.
[0146] Furthermore, in the case of a pharmaceutical composition containing the cells of the present invention, other components may be included, such as dimethyl sulfoxide (DMSO) or serum albumin for the purpose of protecting the cells, or antibiotics for the purpose of preventing bacterial contamination. Furthermore, for the purpose of activating, proliferating, or inducing differentiation of the cells, the composition may also include T cell activating factors such as cytokines, growth factors, and steroids, vitamins, immunostimulants, and immune checkpoint inhibitors, and the cells of the present invention may also be used in combination with these other components.
[0147] The method of administering a pharmaceutical composition varies depending on the type of substance to be administered, the form of the composition, and the age, weight, sex, health condition, etc. of the subject, but can be administered by either parenteral administration (e.g., intravenous administration, intraarterial administration, local administration) or oral administration. Parenteral administration is preferred, and intravenous administration is more preferred. Local administration may also be used instead of systemic administration. An example of local administration is direct injection into the target tissue (such as bone marrow).
[0148] The dosage of the pharmaceutical composition may vary depending on the subject's age, body weight, sex, health condition, degree of progression of symptoms, and the components of the pharmaceutical composition to be administered. The administration schedule is also adjusted appropriately depending on these conditions, and may be a single administration or multiple continuous or periodic administrations. Generally, when an antibody is administered intravenously, the dosage is 0.1 to 1000 mg, preferably 1 to 100 mg, per kg of body weight per day for an adult. When an ADC is administered, the dosage is 0.001 to 1000 mg, preferably 0.01 to 100 mg, per kg of body weight per day for an adult, calculated in terms of the amount of drug contained. These antibodies or ADCs may be administered once, or multiple times at intervals ranging from once a day to once a year (e.g., weekly, every 10 to 30 days, monthly, every 3 to 6 months, every six months, or yearly).
[0149] Furthermore, the dosage of cells (e.g., cells expressing a chimeric antigen receptor) in the treatment method of the present invention is, for example, 1 x 10 cells per kg of body weight in a single administration to an adult. 3 ~1x10 10 pieces (preferably 1x10 4 ~1x10 9pieces, more preferably 1 x 10 5 ~1x10 8 The administration interval can be, for example, once a week, every 10 to 30 days, once a month, every 3 to 6 months, or once a year. Furthermore, since the cells of the present invention can grow autonomously in the body of the recipient, they can be administered only once. Furthermore, the number of cells of the present invention in the body can be monitored after administration, and the timing of administration can be determined based on the results.
[0150] In the present invention, examples of "subjects" to which the antibodies etc. of the present invention are administered include humans suffering from blood cancer etc., humans at risk of recurrence of blood cancer etc., and humans who have recurred blood cancer etc. Furthermore, in the present invention, "treatment" includes alleviating (alleviating) symptoms characteristic of blood cancer etc. or accompanying symptoms, preventing or delaying the worsening of symptoms, improving abnormal clinical test values such as blood cancer cell proliferation, etc. Furthermore, it also includes preventing, delaying, or reducing the risk of recurrence of blood cancer.
[0151] In particular, since the antibody or the like of the present invention can exhibit allele specificity for HLA-DR, in the case of a blood cancer patient or the like who has relapsed after HLA-DR-mismatched allogeneic transplantation, if the recipient (blood cancer patient or the like) has a positive HLA-DR type to which the antibody or the like of the present invention binds, and the donor has a negative HLA-DR type to which the antibody or the like of the present invention does not bind, CAR-T cells or the like produced from cells derived from the transplanted patient or the donor can specifically attack the blood cancer in the recipient.
[0152] Furthermore, the antibody of the present invention binds only to some normal blood cells, such as B cells, and does not bind to monocytes, etc., and only to some hematopoietic stem cells, which are the source of all blood cells. Therefore, even if normal autologous CAR-T cells, etc., of a blood cancer patient, etc., having positive HLA-DR to which the antibody, etc. of the present invention, binds are used for treatment, the blood cancer cells are eliminated and normal hematopoiesis is maintained by negative cells to which the antibody, etc. of the present invention, making it possible to carry out treatment.
[0153] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples. These examples were carried out using the materials and methods shown below.
[0154] (Patient Samples) Bone marrow from patients with acute myeloid leukemia (AML) was collected from the iliac bone after obtaining informed consent. Mononuclear cells were isolated using Ficoll Paque (GE Healthcare) and used for analysis.
[0155] (Preparation of anti-AML monoclonal antibodies) Six-week-old BALB / c mice (CLEA Japan) were immunized by injecting AML cell lines (KG1a, THP-1, U937, HL60, MOLM-13) into the soles of their feet. Lymphocytes collected from popliteal lymph nodes after four immunizations were fused with SP2 / 0 mouse myeloma cells using PEG1500 (Roche Applied Science), and then the cells were seeded in a 96-well plate in HAT medium, and hybridomas were selected. To identify hybridomas producing monoclonal antibodies that bind to AML cells but not to normal blood cells, AML cell lines were first reacted with the monoclonal antibodies in each hybridoma supernatant, followed by reaction with a PE-labeled anti-mouse IgG antibody (BioLegend 405307) and analysis by flow cytometry. Peripheral blood mononuclear cells (PBMCs) from healthy individuals were similarly stained to select hybridomas producing monoclonal antibodies that do not bind to normal blood cells. The cells and supernatants were then preserved and used for subsequent analysis.
[0156] (Flow cytometry analysis) Single cell suspensions were stained with fluorescently labeled antibodies. For staining, anti-CD34-APC (8G12, BD Biosciences), anti-CD38-FITC (HIT2, Biolegend), anti-CD3-Cy7PE (UCHT1, BioLegend), anti-CD19-Cy7APC (HIB19, BioLegend), anti-CD14-BV510 (M5E2, BioLegend), anti-HLA-DR-APC (L243, Biolegend), anti-CD11c-FITC (Bu15, Biolegend), anti-CD19-PE (HIB19, Biolegend), anti-CD279-BV510 (EH12.2H7, Biolegend), anti-CD223-FITC (11C3C65, Biolegend), anti-CD366-PE (F38-2E2, Biolegend), goat anti-mouse IgG-PE (405307, BioLegend), goat anti-mouse F(ab')2-Alexa Fluor 647 (115-605-072, Jackson ImmunoResearch), Biotin-conjugated anti-EGFR antibody (Erbitux), Streptavidin-PE (405204, Biolegend) was used. KG2032 (mouse IgG2a) was purified using Protein G Sepharose 4 Fast Flow (GE Healthcare) and used for staining at a concentration of 10 μg / ml. Analysis and cell sorting were performed using a FACS Canto II or FACS Aria II (BD Bioscience). Data were analyzed using FlowJo software. For analysis using activated T cells, 1 × 10 PBMCs from healthy individuals were used. 6 The cells were stimulated at 1000 kJ / ml in the presence of 3 μg / ml PHA for 3 days.
[0157] (Identification of KG2032 antigen using CRISPR gRNA library) First, a clone of Daudi cells expressing the Cas9 protein was obtained. Specifically, Daudi cells were first infected with a Cas9-expressing lentiviral vector, and 10 μg / ml of blasticidin was added for 4 days to select cells into which the vector had been introduced, followed by single-cell sorting in a 96-well plate. After amplifying them, clones with good knockout efficiency were selected by introducing a Cas9 reporter (Tzelepis K et al., Cell Rep. 2016; 17 (4): 1193-205. See).
[0158] Next, the thus obtained clone of Daudi cells expressing the Cas9 protein was infected with the Human Genome-wide Knockout CRISPR Library (provided by the Yusa Laboratory, Kyoto University) to an efficiency of approximately 30%, and then 0.5 μg / ml of puromycin was added for 3 days to select cells into which the CRISPR library had been introduced. The cells were further expanded to 2 × 10 8 5 × 10 cells were stained with KG2032, and 5% of the KG2032-binding weak fraction (KG2032low) was used. 6 After sorting, DNA was extracted from the sorted cells using DNeasy Blood & Tissue Kits (QIAGEN) and analyzed by NGS. 7 DNA was also extracted from the cells using a Blood & Cell Culture DNA Maxi Kit (QIAGEN) and used as a control.
[0159] (Preparation of knockout cells) Guide RNA (gRNA) for knockout of HLA-DR was synthesized using the GeneArt Precision gRNA Synthesis Kit (Thermo Fisher Scientific). The following two types of gRNA were prepared: gRNA sequence (1): GTGCGCTTCGACAGCGACGT (SEQ ID NO: 31), gRNA sequence (2): GACGGAGCGGGTGCGGTTCC (SEQ ID NO: 32).
[0160] 2 x 10 5 Daudi cells were transfected with 1 μg of TrueCut Cas9 Protein v2 (Thermo Fisher Scientific) and 200 ng of the prepared gRNA using the NEON Transfection System (Invitrogen). After 9 days, the cells were stained with anti-HLA-DR-APC, and the HLA-DR knockout cells were sorted and used for analysis.
[0161] (Identification of the KG2032 epitope) Five types of chimeras, HLA-DRB1*1454 (KG2032-positive) and HLA-DRB1*1502 (KG2032-negative), were generated by overlapping PCR. The generated chimeras were transfected into K562 cells using a retroviral vector, and two days later, the cells were stained with KG2032 and L243, and the presence or absence of binding was analyzed by flow cytometry.
[0162] (Construction and production of chimeric antigen receptor (CAR) 1) cDNA encoding the variable region of KG2032 was obtained by 5' RACE using SMARTer RACE 5' / 3' Kit (Takara), and the sequence was identified. Then, as shown in Figure 8A, the light chain (VL) and heavy chain (VH) were fused via a linker sequence using overlapping PCR. Furthermore, this was fused with CD28 and CD3ζ, or CD8α, 4-1BB and CD3ζ by overlapping PCR ("28ζ" and "BBζ" shown in Figure 8A ), and the fused products were inserted into a retroviral vector to prepare a KG2032-CAR expression vector (also referred to as "KG2032-CD28-CD3ζ-CAR" and "KG2032-BBz-CAR," respectively). To enable measurement of transduction efficiency using an anti-EGFR antibody, an EGFR sequence with its intracellular domain deleted was added after CD3ζ of the KG2032-CAR expression vector, following the T2A sequence.
[0163] (Preparation of CAR-T cells) Each KG2032 CAR expression vector was transfected into 293T cells together with a Gag-pol vector and a VSV-G vector using Lipofectamine 2000 (Invitrogen), and the supernatant was collected 48 and 72 hours later to prepare viral vectors. PBMCs derived from healthy individuals were stimulated with an anti-CD3 antibody (OKT3, eBioscience) and an anti-CD28 antibody (CD28.2, eBioscience) to prepare activated T cells, which were then infected with the virus-containing supernatant. The CAR-transfected T cells were then cultured for 6 days in a medium supplemented with 100 IU / ml of IL-2. When dasatinib was added, it was added at a concentration of 1 μM on days 4-6. On day 6, the CAR transduction efficiency was analyzed using goat anti-mouse F(ab')2-Alexa Fluor 647 (115-605-072, Jackson ImmunoResearch) or biotin-conjugated anti-EGFR antibody.
[0164] (Measurement of cytokine production 1) Cytokine production of KG2032 CAR-T cells or control T cells was measured using a Human IFN-gamma Quantikine ELISA Kit / Human IL-2 Quantikine ELISA Kit (R&D Systems). Specifically, effector cells and target cells were each 1 × 10 5 The cells were co-cultured in a 96-well plate, and the supernatant after 16 to 24 hours was diluted to fall within the range of the standard curve and measured.
[0165] (Measurement of cytotoxic activity 1) The tumor cell cytotoxicity of T cells is 51 Measured by Cr release assay. 5 × 10 5 25 μCi of target cells 51 Cr sodium chromate solution (PerkinElmer) was added, and the mixture was incubated at 37°C for 1.5 hours. 1 x 10 labeled target cells were added. 4 The effector cells were co-cultured with effector cells at various effector / target ratios. After 4 hours, the effector cells were released into the supernatant. 51 Cr was counted using a gamma counter. Total or spontaneous release 51 Cr is labeled 1 x 10 4 The cells were cultured in 1% Triton X-100 or medium and assayed for cytotoxicity. 51 Cr release-spontaneous 51 Cr release) / (total 51 Cr release-spontaneous 51 Cr release)] × 100.
[0166] (Xenograft Mouse Model 1) KG1a-luc / venus was created by introducing a luciferase gene into KG1a cells using a lentiviral vector. Six- to eight-week-old female NOD / SCID / IL-2Rγc null (NOG) mice (CLEA Japan) were irradiated with 1.2 Gy of radiation and then transplanted into 4 × 10 6KG1a cells expressing 1000 luciferase (KG1a-luc / venus) were injected via the tail vein. Five days later, VivoGlo Luciferin (Promega, 150 mg / kg body weight) was administered intraperitoneally, and images were taken using an in vivo imaging system (IVIS) and analyzed using Living Image software (PerkinElmer). The next day, 1-2 x 10 CAR-T cells or control T cells were injected. 6 The patient was administered intravenously and then photographed weekly using IVIS.
[0167] (Construction and Creation of Chimeric Antigen Receptor (CAR) 2) The cDNAs for the light and heavy chain variable regions of KG2032 were fused with the cDNAs for CD28 and CD3ζ by overlap PCR. In addition, the T2A-IL-15 cDNA was also fused to the KG2032 CAR by overlap PCR.
[0168] (Generation of CAR NK Cells) Umbilical cord blood (CB) with KG2032-unreactive HLA was identified by measuring KG2032 reactivity against CD19+ B cells by flow cytometry. T cells were depleted using CD3 MicroBeads (Miltenyi Biotec). T cell-depleted CB mononuclear cells were stimulated with 100 Gy-irradiated K562-mb15-41BBL cells and cultured in the presence of 20 IU / mL of IL-2. One week later, a retrovirus expressing KG2032 CAR-T2A-IL-15 cDNA was transduced into CB-derived NK cells using RetroNectin. The cells were then restimulated with 100 Gy-irradiated K562-mb15-41BBL cells, cultured for an additional week, and used for further experiments.
[0169] (Measurement of cytotoxic activity 2) The tumor cell cytotoxicity of NK cells is 51 Measured by Cr release assay. 6 × 10 5 The target cells were incubated at 37°C for 1.5 hours with 25 μCi of [ 51 The labeled target cells (1 × 10 4) were incubated with effector cells for 4 hours, and the supernatants were collected. 51 Cr release was counted in a gamma counter. 51 Cr release and spontaneous 51 Cr release is 1 × 10 4 The cytotoxic activity was measured by incubating the labeled targets in 1% Triton X-100 or culture medium. 51 Cr release-spontaneous 51 Cr release) / (total 51 Cr release-spontaneous 51 Cr release)] × 100.
[0170] (CD107a degranulation assay) KG2032 CAR NK cells or control NK cells (2.5 × 10 5 cells) were cultured with KG1a AML cells or bone marrow cells from AML patients (5 × 10 4 The cells were co-cultured with CD107a Alexa Fluor 647 (1:50) and monensin (BD Biosciences, 1:1500) in a 96-well plate at an effector:target ratio of 5:1. At the start of culture, anti-CD107a Alexa Fluor 647 (1:50) and monensin (BD Biosciences, 1:1500) were added. After 5 hours of culture, the cells were stained with anti-CD56-PE and analyzed by flow cytometry. The HLA-DR allele type of the AML patient was DRB1*08:02 / 12:01.
[0171] (Xenograft Mouse Model 2) A disseminated AML model was established by intravenously transplanting KG1a AML cells into NOD / SCID / IL-2Rγnull (NOG) mice (In Vivo Science). 1 × 10 cells were injected into 6- to 8-week-old female NOG mice (irradiated 4-24 hours before transplantation at 1.0-2.4 Gy). 6 Luciferase-expressing KG1a cells were injected intravenously via the tail vein. In experiments using KG2032 CAR NK cells, 1.0-1.4 × 10 6KG2032 CAR NK cells or control NK cells were injected on days 1 and 3 after AML cell transplantation. Tumor growth in mice was measured by IVIS by measuring fluorescence emission upon luciferin administration.
[0172] (Generation of modified KG2032 CAR-T cells) The cDNA for the KG2032 CAR was constructed by fusing the variable region cDNAs for the KG2032 light and heavy chains with the CD8α, 4-1BB, and CD3ζ cDNAs by overlap PCR. A mutation to replace tyrosine with phenylalanine within the CD3z ITAM motif in the KG2032 CAR sequence was introduced using the PrimeSTAR Mutagenesis Basal Kit (Takara).
[0173] (Preparation of Single-Cell Suspension of Intestinal Mucosal Epithelial Cells) To prepare a single-cell suspension of intestinal mucosal epithelial cells, the mucosa was cut into 3 mm thick slices, washed three times with phosphate-buffered saline (PBS) (Nacalai Tesque), and incubated in HBSS (Nacalai Tesque) containing 10 mM EDTA at 37°C for 30 minutes. The epithelial cells were then shaken to detach and collected. After centrifugation at 400g for 5 minutes, the cells were suspended in TrypLE Express (Thermo Fisher Scientific) containing 500 U / mL DNase I and incubated at 37°C for 30 minutes to obtain a single-cell suspension. DNA from the intestinal epithelial cells was extracted using the DNeasy Blood & Tissue Kit (QIAGEN). HLA-DRB1 typing was performed at the HLA Research Institute (Kyoto, Japan).
[0174] (Measurement of cytokine production 2) Modified KG2032 CAR-T cells or control T cells were cultured at 1 × 10 intestinal epithelial cells or leukemia cells. 5 The cells were co-cultured with the cells for 16 hours, and the cytokines secreted into the culture supernatant were measured using an ELISA kit (IFN-γ and IL-2; R&D Systems).
[0175] (Measurement of cytotoxic activity 3) The cytotoxic activity of modified KG2032 CAR-T cells was measured by51 6 × 10 5 The target cells were incubated at 37°C for 1.5 hours with 25 μCi of [ 51 The labeled target cells (1 × 10 4 ) was incubated with effector cells for 4 hours, and the supernatant was 51 Cr release was counted in a gamma counter. 51 Cr release and spontaneous 51 Cr release is 1 × 10 4 The cytotoxic activity was measured by incubating the labeled targets in 1% Triton X-100 or culture medium. 51 Cr release - spontaneous 51 Cr release] / [total 51 Cr release - spontaneous 51 The calculation was made as follows: [Cr release] × 100.
[0176] (Xenograft Mouse Model 3) A disseminated AML model was established by intravenously transplanting KG1a AML cells into NOD / SCID / IL-2Rγnull (NOG) mice (In Vivo Science). 1-4 × 10 cells were injected into 6-8 week-old female NOG mice (irradiated 4-24 hours before transplantation with 1.0-2.4 Gy). 6 Luciferase-expressing KG1a cells were injected intravenously via the tail vein. On day 5, mice were intraperitoneally injected with VivoGlo Luciferin (Promega, 150 mg / kg body weight), and tumor growth was measured by observing tumor fluorescence using an in vivo imaging system (IVIS) equipped with Living Image software (PerkinElmer). Mice were then injected with 1.1-2.2 × 10 cells. 6 The modified KG2032 CAR-T cells or control T cells were injected intravenously.
[0177] (Xenograft Mouse Model 4) DNA from AML cells was extracted from the cells using DNeasy Blood & Tissue Kit (QIAGEN). HLA-DRB1 typing was performed at the HLA Research Institute (Kyoto, Japan), and AML cells with KG2032-reactive HLA-DRB1 were used in the experiment. BM cells from AML patients were transplanted into the bone marrow of NOG mice. Female NOG mice aged 6 to 8 weeks were irradiated with 1.2 Gy 4 to 24 hours before transplantation, and then 4 x 105 AML cells, from which CD3-positive T cells had been removed, were injected into the left tibia. Six days later, the mice were injected with 2 x 10 6 Modified KG2032 CAR-T cells or control T cells were intravenously injected. One month after injection, BM cells were stained with anti-human CD45-Cy7APC (2D1, BioLegend), anti-human CD34-APC (8G12, BD Biosciences), anti-human CD3-PE (HIT3a, BioLegend), anti-mouse Ter119-PerCPCy5.5 (Ter-119, BioLegend), and anti-mouse CD45-Cy7PE (30-F11, BioLegend) and analyzed by flow cytometry.
[0178] The results of the experiments carried out using the above materials and methods are shown below.
[0179] (Identification of AML-specific monoclonal antibody KG2032) To obtain AML-specific monoclonal antibodies (mAbs), we first established approximately 14,000 hybridomas secreting monoclonal antibodies (mAbs) that bind to various AML cell lines and AML cells from bone marrow (BM) cells of AML patients.
[0180] Next, we selected 1,078 mAbs that did not bind to cells other than B cells in peripheral blood mononuclear cells (PBMCs) from healthy donors. We then stained BM cells from AML patients with these candidate mAbs and finally identified a clone named KG2032 as a mAb that specifically binds to AML.
[0181] As shown in Figure 1A, KG2032 did not bind to PBMCs from a healthy donor used in screening, whereas as shown in Figure 1B, KG2032 bound to almost all leukemia cells in 7 of 14 AML patients.
[0182] (Identification of the antigen recognized by KG2032) We attempted to identify the antigen recognized by KG2032 using the steps shown in Figure 2A. First, the Human Genome-wide Knockout CRISPR Library was introduced into Daudi cells expressing the Cas9 protein, and the cells into which the library had been introduced were enriched using puromycin. These cells were further expanded to 2 x 10 8 The cells were stained with KG2032, and the 5% fraction of KG2032 was diluted to 5 × 10 6 The cells were sorted (Figure 2B).
[0183] Next, the sequences of the gRNAs introduced into the KG2032low cells before and after sorting were analyzed by next-generation sequencing (NGS). As a result, HLA-DRA, HLA-DRB1, CIITA, and CD74 were identified as molecules targeted by the inserted gRNAs that were significantly enriched in KG2032low cells (Figure 2C). Considering that the latter two are molecules necessary for HLA-DR expression on the cell surface, it was suggested that KG2032 recognizes HLA-DR. Therefore, when the binding of KG2032 to Daudi cells lacking HLA-DR was analyzed, as shown in Figure 2D, no binding was observed, revealing that the antigen recognized by KG2032 is HLA-DR. Furthermore, as shown in Figure 2E, it was revealed that the antigen recognized by 8 clones different from KG2032 out of the 32 clones was also HLA-DR.
[0184] The amino acid sequences of the variable regions of these anti-HLA-DR antibodies of the present invention are shown in the following Tables 1 and 2. Furthermore, the amino acid sequences of the CDRs determined by Kabat from these variable regions are shown in Tables 3 and 4.
[0185]
[0186]
[0187]
[0188]
[0189] (HLA-DRB1 Allele Specificity Recognized by KG2032) Because HLA-DRB1 is a highly polymorphic molecule, we investigated which alleles of HLA-DRB1 are recognized. As a result, as shown in Figure 3, KG2032 bound to K562 cells expressing HLA-DRB1*0404, 0405, 0410, 0803, 0901, or 1454. On the other hand, KG2032 did not bind to K562 cells expressing HLA-DRB1*0101, 0403, 0802, 1101, or 1502.
[0190] Furthermore, as shown in Figure 4A, KG2032 did not bind to any of the PBMC cells from a donor with the KG2032-negative HLA-DRB1 gene (0403 / 0802). Furthermore, when peripheral blood from a donor with the KG2032-positive HLA-DRB1 gene 0901 was stained, binding to B cells and activated T cells was observed, but the binding was extremely weak compared to that of the existing anti-HLA-DR antibody L243.
[0191] Furthermore, as shown in Figure 4A, KG2032 did not bind to some monocytes and T cells to which L243 binds, i.e., to which HLA-DR is expressed. Furthermore, as shown in Figure 4B, binding of KG2032 to leukemia cells was observed in AML patients with KG2032-positive HLA-DRB1 gene.
[0192] When bone marrow cells from a donor carrying the KG2032-positive HLA-DRB1 genes 0410 and 0803 were stained, binding to hematopoietic stem cells (CD34+CD38-) and hematopoietic progenitor cells (CD34+CD38+) was observed, but the binding was extremely weak compared to that of the existing anti-HLA-DR antibody L243. Furthermore, as shown in Figure 4C, KG2032 bound only to a small portion of hematopoietic stem cells to which L243 binds, i.e., expressing HLA-DR.
[0193] Based on these results, the following examples (1) and (2) of using KG2032 in AML treatment are conceivable.
[0194] (1) In an AML patient who has relapsed after HLA-DR-mismatched allogeneic transplantation, if the recipient (leukemia patient) has KG2032-positive HLA-DR and the donor has KG2032-negative HLA-DR, KG2032-derived CAR-T cells produced from T cells derived from the transplanted patient or the donor are thought to specifically attack the recipient's leukemia (Figure 5A).
[0195] (2) In normal blood cells, KG2032 binds only to some cells, such as B cells, and also to only a portion of hematopoietic stem cells, which are the source of all blood cells. Therefore, even if normal autologous CAR-T cells are used for treatment in AML patients with KG2032-positive HLA-DRB1 type, it is thought that leukemia cells will be eliminated and normal hematopoiesis will be maintained by KG2032-negative cells, and therefore, it is considered to be a viable treatment ( Figure 5B ).
[0196] (Identification of the epitope recognized by KG2032) To identify the epitope recognized by KG2032, the amino acid sequences of HLA-DRB1*1454 (KG2032-positive) and HLA-DRB1*1502 (KG2032-negative) were compared (Figure 6). Furthermore, expression vectors expressing chimeric proteins of HLA-DRB1*1454 and HLA-DRB1*1502, as shown in Figure 7A, were constructed by overlapping PCR. These vectors were then retrovirally transfected into K562 cells, and two days later, the cells were stained with KG2032 and L243, and the presence or absence of binding was analyzed by flow cytometry. As a result, as shown in Figure 7B, it was demonstrated that Region 3 (A.A.74-89) shown in Figure 6 is essential for KG2032 binding.
[0197] Furthermore, when the amino acid sequences of Region 3 of HLA-DRB1 to which KG2032 binds were compared with those to which it does not bind, it was found that the amino acid at position 86 is always aspartic acid (D) in HLA-DR to which KG2032 does not bind, whereas it is serine (S), valine (V), or alanine (A) in HLA-DR to which KG2032 binds, as shown in Figure 7C.
[0198] Therefore, we expressed HLA-DRB1*0405, which binds to KG2032, in K562 cells by substituting aspartic acid (D) for serine (S) at position 86. As a result, as shown in Figure 7D, we found that L243 binding was maintained, but KG2032 binding was lost.
[0199] These findings indicate that for KG2032 to bind, the amino acid at position 86 in Region 3 must be an amino acid other than aspartic acid (serine, valine, alanine, etc.).
[0200] (Development of CAR-T cells derived from KG2032-unresponsive DR donors) A chimeric antigen receptor (KG2032-CAR) containing the variable region of KG2032 was prepared. First, cDNA of the variable region of KG2032 was obtained by 5' RACE using SMARTer RACE 5' / 3' Kit (Takara), and the sequence was identified. Next, as shown in Figure 8A, the light chain (VL) and heavy chain (VH) were fused via a linker sequence by overlapping PCR, and then this was fused with CD28 and CD3ζ, or with CD8α, 4-1BB and CD3ζ by overlapping PCR to prepare two types of KG2032-CAR (KG2032-CD28-CD3ζ-CAR, KG2032-BBz-CAR). The structures of these CARs are shown in Table 5 below.
[0201]
[0202] Next, KG2032 CAR was introduced into T lymphocytes derived from a KG2032-negative HLA-DRB1 (0403 / 0802) donor using a retroviral vector to generate KG2032-CAR-T cells ( FIGS. 8B and 8C ).
[0203] As shown in Figures 8D and 8E, the CAR-T cells prepared in this manner produced IFN-γ and IL-2 and exhibited cytotoxic activity when co-cultured with KG1a cells to which KG2032 binds. On the other hand, neither cytokine production nor cytotoxic activity was observed when co-cultured with THP-1 cells to which KG2032 does not bind.
[0204] Note that, since these results were observed regardless of whether the costimulatory molecule was CD28 or 4-1BB, in subsequent experiments, only KG2032-CAR (KG2032-BBz-CAR), in which 4-1BB is the costimulatory molecule, was evaluated.
[0205] Next, we attempted to prevent exhaustion of CAR-T cells by adding dasatinib, a tyrosine kinase inhibitor, during the production of CAR-T cells. As a result, as shown in Figures 8F-H, treatment with 1 μM dasatinib promoted the proliferation of KG2032-BBz-CAR-T cells while reducing the expression of exhaustion marker molecules (PD-1, TIM-3, LAG-3). Furthermore, co-culture with KG1a also increased IL-2 cytokine production.
[0206] Next, luciferase-expressing KG1a cells were transferred into NOG mice, followed by administration of KG2032-BBz CAR-T cells, and the anti-leukemia effect was evaluated. As a result, as shown in Figures 8I and 8J, a significant anti-leukemia effect was observed.
[0207] (Development of CAR-NK cells derived from KG2032-unresponsive DR donors) A vector was constructed for co-expressing a chimeric antigen receptor (CAR) in which CD28 and CD3ζ were fused to the variable region of KG2032, together with IL-15. NK cells expressing this CAR (CAR-NK cells) were then prepared and co-cultured with a human acute myeloid leukemia-derived cell line (KG1a cells). As a result, although not shown in the figure, it was revealed that the CAR-NK cells also exhibited cytotoxic activity. Furthermore, it was revealed that a significant antitumor effect was achieved when the CAR-NK cells were administered to mice into which KG1a cells had been transferred.
[0208] Specifically, the KG2032 CAR construct for CAR-NK cells was prepared by fusing the variable region of KG2032 with CD28 and CD3ζ. Furthermore, to enhance the proliferation and survival of CAR-NK cells, a retroviral vector was designed to co-express IL-15 with the KG2032 CAR. T cells were depleted from human umbilical cord blood (CB) cells bearing KG2032-unreactive HLA-DRB1, and NK cells were expanded by stimulation with irradiated K562 cells expressing 4-1BB ligand and membrane-bound IL-15. After 14 days of culture, CB-derived NK cells retrovirally transduced with KG2032 CAR / IL-15 were analyzed (Figures 9A-9C).
[0209] When cocultured with KG1a cells or patient-derived primary AML cells, CD107a degranulation was significantly increased in KG2032 CAR-NK cells compared to control (non-CAR-transduced) NK cells, but not when cocultured with HLA-DR-deficient KG1a cells (Figure 9D).
[0210] KG2032 CAR-NK cells exhibited significant cytotoxicity against KG1a cells and patient-derived primary AML cells, but not against HLA-DR-deficient KG1a cells (Figure 9E).
[0211] Furthermore, when KG2032 CAR-NK cells were administered to immunodeficient mice transplanted with KG1a AML cells, leukemia cells were significantly reduced and the survival time of the mice was extended (Figures 9F to 9H).
[0212] (Development of Modified KG2032 CAR-T Cells) Because severe cytokine release syndrome (CRS) can increase HLA-DR expression in non-hematologic tissues, severe CRS should be avoided to maximize the safety of KG2032 CAR-T cells. It has been reported that modifying the CAR construct can prevent severe CRS without compromising the efficacy of CAR-T cells (Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med 25, 947-953 (2019). https: / / doi.org:10.1038 / s41591-019-0421-7). Therefore, to reduce cytokine production by CAR-T cells when co-cultured with AML cells, we modified the KG2032 CAR construct by changing the order of the heavy chain (VH) and light chain (VL) in the antigen recognition domain and extending the length of the CD8α hinge / transmembrane domain. Furthermore, to weaken the CAR activation signal, we introduced mutations into two of the three immunoreceptor tyrosine-based activation motif (ITAM) domains in the CD3ζ sequence (Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fate and therapeutic potency. Nat Med 25, 82-88 (2019)). The structure of this modified KG2032 CAR is shown in Table 5 above.
[0213] First, we analyzed the secretion of IFN-γ by the original or modified KG2032 CAR-T cells after coculture with KG1a AML cells. As a result, IFN-γ secretion by the modified KG2032 CAR-T cells was reduced compared to that by the original cells, confirming that the mutation weakened the CAR activation signal.
[0214] Next, the amounts of IFN-γ and IL-2 secreted by modified KG2032 CAR-T cells were analyzed after co-culture with normal intestinal epithelial cells or KG1a cells purified from normal small intestine obtained from resected specimens of colorectal cancer patients. The results showed that modified KG2032 CAR-T cells were not activated when co-cultured with normal intestinal epithelial cells bearing KG2032-reactive HLA-DRB1. On the other hand, modified KG2032 CAR-T cells retained cytotoxic activity against KG1a AML cells and patient-derived primary AML cells.
[0215] Furthermore, modified KG2032 CAR-T cells were administered to mice transplanted with KG1a AML cells. As a result, administration of modified KG2032 CAR-T cells significantly reduced the number of KG1a AML cells engrafted in the mice and extended their survival time. Furthermore, no obvious toxicity was observed in mice treated with modified KG2032 CAR-T cells.
[0216] Furthermore, the modified KG2032 CAR-T cells were administered to immunodeficient mice transplanted with patient-derived AML cells ( Figure 10A ). As a result, the modified KG2032 CAR-T cells eradicated the patient-derived AML cells transplanted into the immunodeficient mice ( Figures 10B and 10C ). No obvious toxicity was observed in the mice administered with the modified KG2032 CAR-T cells.
[0217] As described above, according to the present invention, by targeting HLA-DR, which is a cell surface antigen specific to blood cancers such as acute myeloid leukemia, it becomes possible to treat such diseases by using an antibody or a functional fragment thereof that recognizes the antigen, or a chimeric antigen receptor (CAR) that retains the same.
[0218] In particular, since such antibodies can exhibit allele specificity for HLA-DR, in the case of a blood cancer patient who has relapsed after HLA-DR-mismatched allogeneic transplantation, if the recipient (blood cancer patient) has positive HLA-DR to which the antibody of the present invention binds and the donor has negative HLA-DR to which the antibody of the present invention does not bind, CAR-T cells or the like derived from the antibody of the present invention produced from donor-derived cells can specifically attack blood cancer cells of the recipient.
[0219] Furthermore, when the antibody of the present invention binds only to some normal blood cells, such as B cells, and does not bind to monocytes and the like, even if normal autologous CAR-T cells or the like of a blood cancer patient having positive HLA-DR to which the antibody of the present invention binds are used for treatment, the blood cancer cells will be eliminated and normal hematopoiesis will be maintained by negative cells to which the antibody of the present invention does not bind, making treatment possible.
[0220] Therefore, the present invention is useful for therapeutic agents for blood cancer and for the development thereof.
Claims
1. A composition for treating blood cancer, comprising an antibody or a functional fragment thereof that recognizes HLA-DR.
2. The composition of claim 1, comprising an immune cell expressing a chimeric antigen receptor bearing the antibody or a functional fragment thereof.
3. The composition according to claim 1, comprising a multispecific antibody that retains the antibody or a functional fragment thereof and an antigen recognition site on an immune cell.
4. The composition of claim 1, wherein the antibody or functional fragment thereof does not bind to monocytes.
5. The composition according to claim 4, comprising an immune cell expressing a chimeric antigen receptor bearing the antibody or a functional fragment thereof.
6. The composition according to claim 4, comprising a multispecific antibody that retains the antibody or a functional fragment thereof and an antigen recognition site on an immune cell.
7. The composition according to claim 1, wherein the antibody or functional fragment thereof binds to an allele of HLA-DRB1 in which position 86 is an amino acid other than aspartic acid, but does not bind to an allele of HLA-DRB1 in which position 86 is aspartic acid.
8. The composition according to claim 1, wherein the antibody or functional fragment thereof binds to a region comprising the amino acid sequence of positions 74 to 89 of HLA-DRB1 in which the amino acid at position 86 is an amino acid other than aspartic acid, but does not bind to a region comprising the amino acid sequence of positions 74 to 89 of HLA-DRB1 in which the amino acid at position 86 is aspartic acid.
9. An antibody or functional fragment thereof that recognizes HLA-DR, having any of the following characteristics (a) to (i): (a) having a heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 1 to 3, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 5 to 7; (b) having a heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 34 to 36, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 38 to 40; (c) having a heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 42 to 44, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 46 to 48. (d) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 50 to 52, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 54 to 56. (e) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 58 to 60, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62 to 64. (f) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 66 to 68, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62 to 64. (g) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 70 to 72, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62 to 64. (h) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 74 to 76, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62 to 64. (i) A heavy chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 66 to 68, and a light chain variable region comprising complementarity determining regions 1 to 3 each comprising the amino acid sequences set forth in SEQ ID NOs: 62, 78, and 64.
10. An immune cell expressing a chimeric antigen receptor carrying the antibody or functional fragment thereof according to claim 8 or 9.
11. A pharmaceutical composition comprising the antibody or functional fragment thereof according to claim 8 or 9, or an immune cell expressing a chimeric antigen receptor comprising said antibody or functional fragment thereof.
12. A composition to be administered to a patient with blood cancer who has received a hematopoietic stem cell transplant, comprising an antibody or a functional fragment thereof that recognizes HLA-DR, wherein the donor of the hematopoietic stem cells and the patient have different HLA-DR allele types, and the antibody or functional fragment thereof binds to the patient's HLA-DR but does not bind to the donor's HLA-DR.
